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Thesis Abstract 
 Most cancer treatments are genotoxic agents that target and damage DNA as part 
of their mechanism of action. Recently, it was discovered that cancer cells with damaged 
DNA can escape the DNA damage checkpoint and enter into mitosis, a process known as 
checkpoint adaptation. I used the human colon carcinoma cell line (HT-29) as a model to 
examine checkpoint adaptation in cells treated with camptothecin (CPT), a topoisomerase 
I inhibitor that damages DNA. Survival and clonogenic assays revealed that 
approximately between 1-3% of the cells that undergo checkpoint adaptation are able to 
survive CPT treatment. Immunofluorescence microscopy disclosed that approximately 
90% of the surviving cells were negative for histone γ-H2AX, whereas, in parallel, the 
alkaline comet assay revealed that 73% of the cells displayed comets.  Karyotype analysis 
showed survival cells had 35 chromosomes on average, whereas non-treated cells 
contained 65.  FISH analysis revealed that survival cells appear to have major changes in 
chromosome structure because 45% of the chromosomes were missing telomeres and 
28% of the telomeres were located in positions other than the tips of chromosomes.  
These findings provide valuable information about the integrity of the genome of cancer 
cells that survive checkpoint adaptation.   
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Chapter 1 
1. Literature Review  
 
 This thesis is about human cancer cells that survive checkpoint adaptation.  To 
understand checkpoint adaptation, I will describe a cellular perspective of cancer, 
techniques that can be used to detect damaged DNA, and how cells respond to cytotoxic 
cancer drugs.   
One of the features of cancer cells is that they contain many mutations in their 
genome (Kandoth et al., 2013).  Some of these mutations disrupt the normal biochemical 
pathways that control the process of the cell cycle.  As a result, many types of cancer cells 
proliferate in a manner that is different from that of normal cells, leading to uncontrolled 
tumour growth.  Another feature of cancer cells is genomic instability, which is believed 
to be in part linked to cell cycle deregulation (Hanahan and Weinberg, 2011).  
Understanding of the relationship between the cell cycle and genomic change in normal 
and cancerous cells will make it possible to one day exploit these differences and provide 
better treatments for cancer patients.  In the following sections, I will describe the cell 
cycle, DNA damage pathways, chromothripsis, and the relationship between these 
processes, with the goal to understand better the role of checkpoint adaptation in human 
cancer cells.  In the Results section that follows, I will describe experiments that we 
performed to answer questions about checkpoint adaptation and cancer cells that survive 
cytotoxic cancer treatments.  
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1.1 The Cell Cycle 
 The cell cycle is an orderly sequence of events, known as phases, in which a cell 
grows, replicates its DNA, and produces two genetically identical cells.  Defects in cell 
cycle regulation may cause unscheduled proliferation and genomic instability, giving rise 
to cancer cells (Cerveira et al., 2012).  The four phases of the cell cycle are: G1 phase, S-
phase, G2 phase, and M-phase (Figure 1) (Norbury and Nurse, 1992).  At the end of 
mitosis the cell undergoes cytokinesis, which is the process that forms two cells, each 
with a complete genome.  Of the four phases, the first three do not give rise to 
morphological changes that can be observed by light microscopy.  By contrast, the M-
phase produces a dramatic change in cell shape and chromosome condensation, which are 
readily observed by light microscopy.  These features led to a historical classification of 
the cell cycle that is still used today: interphase (G1, S and G2 phases) and mitosis (M-
phase).  As will be shown, in our study of checkpoint adaptation, we used morphology 
changes to describe cells as interphasic or mitotic and prepare experiments based upon 
mitotic cells.    
 
 
1.1.1  Interphase 
 Human cells, like most eukaryotic cells, begin the cell cycle in G1, which 
occupies the majority of their time in the cell cycle (Norbury and Nurse, 1992).  During 
the G1 phase a cell grows by synthesis of bio-molecules, such as proteins and lipids (but 
not DNA), to almost double its original size (Vermeulen et al., 2003).  The synthesis of  
 3 
 
 
 
 
 
 
Figure 1. An overview of the cell cycle.  The four phases of the cell cycle and their order 
are shown.  The genome is duplicated during S-phase and segregated into two, separate 
copies during M-phase.  At the end of M-phase, cells undergo cytokinesis to form two 
daughter cells (not shown) and exit the cell cycle as a G0 phase until the cell resumes 
proliferation.  The transition from the G2-phase to M-phase is regulated by one of the 
DNA damage checkpoints (blue arrow).  In the presence of damaged DNA, cells remain 
in the G2-phase.   
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DNA is specific to the S-phase of the cell cycle (the synthesis phase) (Cerveira et al., 
2012).  During S-phase, the entire genome is copied once by template directed 
polymerization.  After the two copies of DNA are synthesized, the cell exits the S-phase 
and enters the G2-phase. During this phase, the cell can grow, but it specifically prepares 
for M-phase by synthesising M-phase specific proteins.  Although the distinctive 
biochemical features of the G1, S, and G2 phases are now well described, the morphology 
of the cell changes little during these phases.  Typically for human epithelial cells, such as 
the ones we used in experiments in this thesis, interphase cells are adherent, flattened, and 
have visible nucleus.     
 
 
1.1.2 M-Phase 
 The last phase of the cell cycle is the M-phase.  In this phase, one complete copy 
of the genome is carefully segregated and distributed to opposite poles of a cell. This 
process is coordinated with cytokinesis to ensure that each daughter cell has one complete 
copy of the genome (Rieder and Khodjakov, 2003).  Mitosis is characterized by several 
well defined processes: condensation of chromosomes into mitotic chromosomes; 
breakdown of the nuclear envelope; alignment of paired chromosomes; followed by 
separation of the sister chromatids to opposite poles of the cell; and re-formation of nuclei 
(Rieder and Khodjakov, 2003).  
 Cells in mitosis have a rounded morphology that distinguishes them from cells in 
interphase (Harris et al., 1973).  Cell rounding enables the cell to generate a mitotic 
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spindle, which is essential for a successful cell division (Lancaster et al., 2013).  As will 
be described later, the rounded morphology of mitotic cells was a characteristic that 
enabled me to examine checkpoint adaptation and cell survival.   
 Mitosis can also be characterized by several biochemical features in addition to 
changes in morphology.  For example, mitotic cells have high levels of cyclin B1, Cdk1 
activity, and high levels of phosphorylated ser10 (Pines and Hunter, 1989; Meijer et al., 
1989; Hendzel et al., 1997).  These features make it possible to identify and follow cells 
as they enter into mitosis, in both normal dividing cells (Juan et al., 1998) and cells that 
contain damaged DNA (Syljuåsen et al., 2006; Kubara et al., 2012). 
 
 
1.2 Cell Cycle Regulators 
 The transition between cell cycle phases is tightly regulated by cyclin dependent 
kinases (Cdk).  The role of Cdks is to control cell cycle progression by phosphorylation of 
protein substrates on serine and threonine amino acids.  The protein substrates have 
specific roles that contribute to the cellular events that occur during the cell cycle.  For 
example, lamin B protein is phosphorylated by Cdk1 during mitosis, which causes 
nuclear envelope breakdown (Nigg, 1995).  The correct timing of cell cycle phase 
changes is regulated by specific cyclin dependent protein kinase complexes.  Cyclin 
dependent kinases are composed of two proteins: a catalytic subunit known as Cdk and a 
regulatory protein subunit known as cyclin (Kastan and Bartek, 2004).  The cyclin 
proteins do not have enzymatic activity; however, they bind and activate the catalytic 
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subunits.  At least 25 catalytic Cdks have been described, and each binds to at least one of 
a large family of cyclin binding partners, creating many possibilities for Cdk cyclin 
protein pairings (Bruyere and Meijer, 2013).  The timing of the synthesis of specific 
cyclins is carefully regulated, which ensures that certain Cdk-cyclin complexes trigger 
different stages of cell cycle.  For example, the Cdk4/cyclin D complex functions early in 
the G1 phase of the cell cycle in response to growth factors, whereas Cdk1/cyclin B 
complex enables cells to enter mitosis.  
 There are several biochemical steps required to activate Cdks in addition to cyclin 
synthesis, thus ensuring cell cycle fidelity.  In one example, Cdk1 is phosphorylated on 
threonine 14 and tyrosine 15 by the cell cycle protein kinases Wee1 and Mik1 (Lundgren 
et al., 1991).  When phosphorylated on these amino acids, Cdk1 remains inactive even 
though it is bound to a cyclin.  Cdk1 can be dephosphorylated at these sites by members 
of the Cdc25 protein phosphatases (Strausfeld et al., 1991).  This additional level of 
control enables cells to accumulate Cdk complexes and activate them in a short time.  The 
cell is blocked in the G2 phase of the cell cycle if Cdk1 remains phosphorylated on 
tyrosine 15, which holds the enzyme in an inactive state regardless of cyclin B1 levels.   
Eukaryotic cells (including human cells) have a second biochemical system that 
can regulate Cdk activity if the cell has damaged DNA (Smith et al., 2010).  Another 
protein kinase, Chk1 (Checkpoint kinase 1), can prevent the activation of Cdk1 by 
phosphorylating and promoting the degradation of Cdc25 phosphatases (Mailand et al., 
2000; Busino et al., 2003; Sorensen et al., 2003). Without Cdc25 phosphatases, cells 
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cannot dephosphorylate tyrosine 15 of the catalytic subunit of Cdk1, thus remain blocked 
in interphase, usually the G2-phase.   
 Overall, a series of protein phosphorylation and protein synthesis pathways 
converge to regulate cyclin dependent protein kinases.  It appears that the complexity of 
these steps provides cells with opportunities to ensure that their genomes are accurately 
copied and distributed to daughter cells, while avoiding genome change.  In my thesis, I 
focus on checkpoint adaptation, which is at the interface of cell cycle arrest by damaged 
DNA and entry into mitosis.  Therefore, I will describe some of the key proteins that are 
required to study this event.   
 
 
1.3 Cell Cycle Checkpoints 
 In addition to cell cycle regulators, appropriate progression through the cell cycle 
is tightly monitored by a series of checkpoints.  Cell cycle checkpoints are biochemical 
pathways that detect physiological changes in cells.  The cell must then respond to these 
changes before it can proceed into the next stage, for example, before it can exit G2 phase 
and enter mitosis (Hartwell and Weinert, 1989).  There are at least three checkpoints in 
higher eukaryotic cells, each with distinct but sometimes overlapping roles.  The first is 
the restriction point, which is a special case because it determines if a cell will enter the 
cell cycle or not.  At the transition between the G1 and S phase, the restriction point is 
when cells are examined for normal growth patterns, potential space limitations and 
genome integrity (Weinert, 1998).  The cell responds as if it makes a “decision” as to 
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whether the cell should divide, delay division or exit the cell cycle as a G0 phase.  When 
conditions in the cells are right, the restriction point will be passed and the cell will be 
committed to enter the cell cycle and enter into the S phase (Figure 1) (Abraham, 2001).   
 
 
1.3.1  The Spindle Assembly Checkpoint    
 The spindle assembly is a second checkpoint that monitors chromosome 
attachment and chromosome segregation during mitosis to ensure that the daughter cells 
receive a complete chromosome set (Rudner and Murray, 1996).  Defects in spindle 
structure or failure of one or more chromosomes to align properly on the spindle are 
detected at the spindle assembly checkpoint, delaying mitosis usually until the defect is 
corrected (Gonzalez et al., 2012).  Malfunction in the spindle assembly checkpoint can 
lead to improper chromosome segregation, aneuploidy, cancer or even cell death 
(Abraham, 2001).  Checkpoint adaptation occurs prior to the spindle checkpoint; 
therefore, despite the close temporal relationship between the two (a mitotic event), 
failure of this type of checkpoint is not directly related to checkpoint adaptation (On et 
al., 2011).  By contrast, it is believed that the DNA damage checkpoint may impact the 
mitotic checkpoint; however, this topic has yet to be adequately investigated (Andreassen 
et al., 2003). 
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1.3.2 DNA Damage Checkpoints 
 Cells with damaged DNA initiate a biochemical pathway called the “DNA damage 
checkpoint”, which causes a delay in the cell cycle during S-phase or G2 phase to allow 
repair (Galgoczy and Toczyski, 2001; Weinert, 1998).  It is believed that the role of DNA 
damage checkpoints is to prevent damaged DNA from being transmitted to daughter cells 
(Bartek and Lukas, 2007).  The DNA damage checkpoint is composed of several 
overlapping checkpoint systems.  An S-phase checkpoint provides continual monitoring 
of the DNA during DNA replication to ensure that blocked replication complexes or 
damaged DNA are repaired before replication (Palou et al., 2010).    
 The successful completion of DNA replication is assessed in the G2 checkpoint.  
The G2 checkpoint enables cells to detect un-replicated DNA or DNA that may have been 
damaged by a variety of means such as genotoxic agents (Vermeulen et al., 2003).  The 
cell will delay its progression through the cell cycle at the G2 phase until errors are 
corrected.   
 
 
1.3.2.1  G2 DNA Damage Checkpoint 
 The G2 DNA damage checkpoint inhibits the initiation of mitosis in cells that 
contain damaged DNA (Melo and Toczyski, 2002).  By arresting the cell in the G2-phase, 
the cell can repair the damaged DNA prior to distributing it to daughter cells during 
mitosis.  The G2 checkpoint protects multicellular organisms by acting as a major barrier 
to the propagation of genomic change in proliferating cells (Bartkova et al., 2005).  It is a 
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reasonable assumption that the inactivation or failure of the G2 checkpoint might then be 
a source of genetic change in cells (Syljuåsen, 2007).  
The DNA damage checkpoint can stop the cell cycle to prevent damaged DNA 
from being transmitted to daughter cells (Kastan and Bartek, 2004).  This process 
operates by a molecular system of proteins that act as sensors of damaged DNA and 
effectors to repair the damage or stop the cell cycle (Melo and Toczyski, 2002).  The 
sensors of damaged DNA are members of the PI(3)kinase-like kinase family: ATM 
(ataxia-telangiectasia mutated); ATR (ATM- and Rad3-related); and DNA-dependent 
protein kinase (Smith et al., 2010).  These kinases interact with adaptors at sites of 
damaged DNA and phosphorylate other proteins that act as effectors of the DNA damage 
signal.  For example, ATR phosphorylates checkpoint kinase 1 (Chk1) on serine 317 and 
serine 345, and ATM phosphorylates checkpoint kinase 2 (Chk2) on threonine 68.  It is 
the type of DNA damage that determines which subset pathway will be activated.  Breaks 
in double-stranded DNA activate ATM, whereas damage acquired during replication 
activates ATR (Liu et al., 2000).  However, ATR can also be activated after ATM, even 
when cells have one type of DNA damage, leading to crosstalk between these pathways 
(Jazayeri et al., 2006). 
The activation of the effector proteins has important consequences upon the cell 
cycle.  One key protein, a multifunctional transcription factor, p53, becomes stabilized 
and directs the expression of p21, a protein that can inhibit Cdk2 complexes, thereby 
blocking cells in G1/S-phase of the cell cycle.  In cancer cells, p53 is frequently 
inactivated by mutation (Weinstein et al., 2013).  The remaining functional effectors of 
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the DNA damage checkpoint are Chk1 and Chk2, which highlights their importance in 
cancer cells.  Phosphorylation of Chk1 and Chk2 results in their activation and leads to 
the phosphorylation and inactivation of Cdc25 phosphatases.  This is a point where the 
cell cycle and the DNA damage pathways meet.  The reduction of Cdc25 phosphatase 
activity causes Cdk1/cyclin B to accumulate and remain inactive.  Currently, Chk2 is 
believed to have a less important role relative to Chk1 in entry into mitosis (Morgan et 
al., 2006).  
Upon exposure to genotoxic agents, ATM and ATR also phosphorylate histone 
H2AX on serine-139 and convert it into histone γ-H2AX (Fernandez-Capetillo et al., 
2004).  Histone H2AX phosphorylation occurs within minutes of a DNA damage event 
and is one of the key steps in the DNA damage response in human cells.  The 
organization of histone γ-H2AX can take two forms in human cells with damaged DNA.  
In one case, histone γ-H2AX molecules are organized at sites of double stranded DNA 
breaks, where they recruit DNA repair and signaling molecules.  These sites are visible as 
foci by use of specific antibodies to histone γ-H2AX and fluorescent microscopy, because 
the protein inserts at sites within two megabases of DNA from the break (Fernandez-
Capetillo et al., 2004).  A second type of organization is diffuse pan-nuclear staining, in 
which histone γ-H2AX is found throughout the nucleus of a cell with damaged DNA.  
Although foci may form after short exposures to genotoxic agents, pan-nuclear staining 
occurs later on after exposure to some genotoxic agents, such as camptothecin (Furuta et 
al., 2003), which reflect times observed in pharmacokinetic studies (Rivory et al., 1997).  
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  In the HT-29 cell model that I use, histone γ-H2AX organization occurs as pan 
nuclear staining in cells that treated with clinically relevant amounts of genotoxic drugs 
such as camptothecin, etoposide or alkylating agents (Leonce et al., 2006; Cahuzac et al., 
2010).  Cells that have cytotoxic amounts of damaged DNA contain histone γ-H2AX 
levels that are readily distinguished from cells in mitosis (Ferry et al., 2011).  Histone γ-
H2AX foci are present in small numbers and low intensity in cells that are in mitosis; 
therefore, it is necessary to perform tests in parallel with non-treated mitotic cells to cells 
treated with genotoxic agents (McManus and Hendzel, 2005).  Because of the rapid 
induction of histone γ-H2AX and its activation by nearly all genotoxic agents, histone γ-
H2AX has become a standard marker for the presence of damaged DNA (Rogakou et al., 
1998; Fernandez-Capetillo et al., 2004; Bonner et al., 2008).   
 
 
1.4 DNA Damaging Agents  
 The cells of our body are continuously challenged by agents and chemicals that 
damage DNA (Holland et al., 2011).  Some agents are from natural sources that we 
cannot avoid such as ultra violet energy from the sun (Holland et al., 2011).  Other 
genotoxic agents, such as camptothecin (CPT), are medically important, and used in 
cancer treatment.  The majority of current cancer treatments are based upon genotoxic 
agents as a means to stop the growth of cancer cells (Siegel et al., 2011).    
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 In the experiments described in my thesis, we used CPT as the genotoxic agent 
because its mechanism of action is well characterized; it is also inexpensive and easily 
administered to cultured cells.  CPT was first isolated by Wall et al. (1966) from extracts 
from a tree native to China called Camptotheca acuminate.  CPT has been confirmed to 
be effective against an extensive range of tumors (Liu et al., 2000).  The 
pharmacokinetics of CPT has been investigated widely in humans to examine the 
genotoxic reaction in cancer cells (Pizzolato and Saltz, 2003).  The primary cellular target 
of CPT is the enzyme topoisomerase I (Topo I) (Li et al., 2006; Smith et al., 1989).  Topo 
I removes the DNA supercoil by cutting a single strand of the DNA double helix to relax 
the strand during transcription and DNA replication (Roca, 1995; Champoux, 2001).  
Once the DNA is relaxed, Topo-I religates the breaks by reversing its covalent binding 
(Pommier, 2006).  Religation requires the 5’- hydroxyl group at the DNA end to be 
aligned with the tyrosine-DNA phosphodiester bond.  CPT inhibits Topo I by blocking 
the rejoining step of the religation reaction of Topo I.  CPT forms a ternary complex with 
topoisomerase I and single-stranded DNA (Hsiang et al., 1989). This ternary complex 
stabilizes the covalent binding of Topo I to the 3’ end of the broken DNA, which blocks 
DNA religation and generates irreversible double-strand breaks (Hsiang et al., 1989; Liu 
et al., 2000).   
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1.5 Outcomes of Initiating the G2 DNA Damage Checkpoint 
 The G2 DNA damage checkpoint is associated with biochemical pathways that 
delay or arrest the cell cycle progression or trigger cell death pathways, depending on the 
severity of the DNA damage (Niida and Nakanishi, 2006).  There are three potential 
consequences of the G2 DNA damage checkpoint (Zhou and Elledge, 2000).  The first is 
checkpoint recovery, in which the G2 DNA damage checkpoint delays the cell cycle 
progression, the damaged DNA is repaired, and the DNA damage checkpoint sensors 
become inactivated as the repair is completed. This inactivation enables cells to exit the 
G2 block and enter into mitosis (Clemenson and Marsolier-Kergoat, 2009).  Another 
possible outcome is cell death, in which the cell is unable to repair the damaged DNA, so 
it initiates cell death via apoptosis, necrosis or by means such as the poorly characterized 
mitotic catastrophe (Castedo et al., 2004; Vakifahmetoglu et al., 2008).  In either of these 
events, the cell does not distribute a damaged genome to the daughter cells.  The third 
outcome of the G2 DNA damage checkpoint is termed as checkpoint adaptation 
(Toczyski et al., 1997).   
 
 
1.6 Checkpoint Adaptation  
The process by which cells escape from the DNA damage checkpoint and enter 
into mitosis while DNA is still damaged is known as checkpoint adaptation (Clemenson 
and Marsolier-Kergoat, 2009).  Checkpoint adaptation was originally detected in the yeast 
Saccharomyces cerevisiae (Sandell and Zakian, 1993).  In this study, one telomere was 
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eliminated from the ends of dispensable yeast chromosomes by constructing experimental 
strains.  The elimination of telomeres initially caused cell cycle arrest, induced by the 
DNA damage pathway.  Nevertheless, many cells escaped the DNA damage checkpoint 
arrest without repairing the damaged chromosome.  Eventually the cells with damaged 
chromosomes restarted the cell cycle, entered mitosis and made daughter cells. These 
cells had the ability to divide in spite of persistent DNA damage.   
 Checkpoint adaptation has also been observed in Xenopus egg extracts, which 
displayed a phenomenon equivalent to adaptation in yeast (Yoo et al., 2004).  In this 
study, the authors treated the Xenopus egg extracts with the DNA polymerase inhibitor, 
aphidicolin.  They observed that after a prolonged G1/S-phase arrest, treated egg extracts 
were able to enter into a mitosis-equivalent state despite of the presence of incompletely 
replicated DNA.  The illustration of checkpoint adaptation in yeast and Xenopus egg 
extracts raised the question of whether checkpoint adaptation could occur in human cells. 
 
 
1.6.1 Checkpoint Adaptation in Human Cells       
 Checkpoint adaptation in human cells was first reported by testing osteosarcoma 
cells (U2OS) exposed to ionizing radiation (Syljuåsen et al., 2006). Ionizing radiation 
generated DNA double-strand breaks, which activated the DNA damage checkpoint and 
caused a G2 arrest. Later on after exposure, however, the cells entered into mitosis while 
their DNA was still damaged.  By using immunofluorescence microscopy, the research 
group showed that treated mitotic cells were positive for histone γ-H2AX staining which 
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means that the cells had damaged DNA.  It was unclear, however, if checkpoint 
adaptation was a key event as they did not measure which proportion of the cell 
population entered into mitosis with damaged DNA.  Syljuåsen et al. (2006) predicted 
that checkpoint adaptation can potentially cause genomic instability and lead to cancer 
development.  
Since 2006, checkpoint adaptation has been described to occur in several other 
cancer cell lines, including HeLa, lymphocytic leukemia and colon carcinoma (Syljuåsen 
et al., 2006; Cahuzac et al., 2010; Rezacova et al., 2011; Kubara et al., 2012).  In these 
experiments, the three criteria of checkpoint adaptation were examined: 1) a cell cycle 
arrest in G2 phase, 2) entry into mitosis by escaping the G2 arrest, and 3) damaged DNA 
in mitotic cells (Toczyski et al., 1997).  Lymphocytic leukemia cells (MOLT4) treated 
with fractionated radiation (small radiation doses delivered over several days instead of 
one large dose of radiation) arrested in S or G2 phases as determined by cell counting and 
flow cytometry (Rezacova et al., 2011).  MOLT4 cells were able to escape the arrest and 
enter into mitosis with double strand breaks (DSB) as detected by histone γ-H2AX 
immunofluorescence microscopy and by Western blotting of cyclin B protein. 
Checkpoint adaptation has also been demonstrated in the human colon carcinoma 
cell line (HT-29) by Kubara et al. (2012). HT-29 cells treated with pharmacologically 
relevant concentrations of CPT underwent checkpoint adaptation as defined by the three 
criteria.  A study on normal human fibroblastic cells demonstrated that checkpoint 
adaptation also occurs in non-cancerous human cells (Rezacova et al., 2011).  Similar to 
the MOLT4 cells described above, fibroblasts were treated with fractionated radiation to 
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create DNA double strand breaks.  It was reported that this cell line underwent checkpoint 
adaptation, although there was no evidence of a delay in the cell cycle, activation of a 
checkpoint, or entry into mitosis.  Damaged DNA was detected, however, by histone γ-
H2AX immunofluorescence microscopy.  Therefore, further studies are needed to 
determine if normal human fibroblastic cells undergo checkpoint adaptation.  
It is likely that checkpoint adaptation also occurs in other cell types based upon 
descriptions of genotoxic treatments that cause cells to enter mitosis; however, few 
studies examine the three criteria required to meet the definition of checkpoint adaptation.  
In an example, a study on metastatic hepatocellular carcinoma (HCC) cells treated with 
cytotoxic concentrations of cisplatin entered mitosis as a result of changes in Cdc25A 
activity (Wang et al., 2008).  In support of the possibility that checkpoint adaptation is a 
common event, numerous studies of cells treated with genotoxic agents describe an 
increase in Cdk1 enzyme activity as a step in the toxicological cellular response.  
Knowing that Cdk1 is solely required for mitosis, it is possible that in some cases, authors 
are indirectly detecting cells that enter mitosis with damaged DNA (Golsteyn, 2005).  
These observations highlighted a need to understand the process of checkpoint adaptation 
in human cancer cells.   
 
 
1.6.2 Consequences of Checkpoint Adaptation  
 A number of questions have arisen since the demonstration of checkpoint 
adaptation in human cells:  
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1. Does it happen in all human cancer cell lines, or is this specific to 
certain cell types? 
2. Do cells survive checkpoint adaptation? 
3. If cells survive, are they changed by this process? 
The mechanism of checkpoint adaptation in which cells can enter into mitosis with 
damaged DNA and the biological significance of this phenomenon are largely unknown.  
Although the majority of cells that undergo checkpoint adaptation will die, it was 
predicted that some of them will survive and that these might have damaged DNA 
(Syljuåsen et al., 2006; Kubara et al., 2012).  In addition, it is widely known that patients 
treated with genotoxic cancer drugs may acquire tumours that are genetically different 
from the primary tumour (Kastan and Bartek, 2004; Bartek and Lukas, 2007; Nakada et 
al., 2006).  It is possible that checkpoint adaptation might contribute to this phenomenon 
(Syljuåsen, 2007; Kubara et al., 2012).  
 
 
1.7 Colorectal Cancer 
Colorectal cancer is the second most common cause of cancer death for males and 
the third most common cause of cancer death for females in Canada (Canadian Cancer 
Statistics, 2013).  One in 13 Canadian males and 1 in 15 Canadian females are expected 
to be diagnosed with colorectal cancer during their lifetime.  Both environmental factors 
such as diet and smoking, as well as genetic factors, play important role in the 
development of colon cancer.  Colon cancer starts with small non-cancerous growths 
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called polyps that appeared in the colon.  Colorectal cancer follows the multi-stage 
model, initially affecting normal mucosa and finally becoming an invasive 
adenocarcinoma (Mustafa et al., 2013).  This sequence of events happens as a result of 
the accumulation of genetic aberrations, which ultimately leads to dysfunctional changes 
in proliferation, differentiation and apoptosis.  Over a period of several years, the rate of 
cell growth and apoptosis results in the development of cancerous polyps. A cancerous 
polyp grows rapidly inside, eventually breaking through the wall of the colon and 
spreading via lymph vessels and blood vessels to other parts of the body.   
To study checkpoint adaptation, I needed to use a model that would represent 
features of the human disease while being suitable to experimental conditions in a 
laboratory.  In this research, I have worked with the human colon adenocarcinoma cell 
line, known as the HT-29 cell line. The HT-29 cell model provides several advantages 
over the first cell model (U2OS) that was described by Syljuåsen et al. (2006).  HT-29 
cells are representative of human colon cancer, respond to camptothecin, and undergo a 
pronounced morphology change when entering mitosis.  HT-29 cells were derived from a 
primary adenocarcinoma of the rectosigmoid colon.  HT-29 is hypertriploid (3n+) and has 
accumulated numerous chromosomal structural aberrations (Kawai et al., 2002).  The 
typical chromosome number of the HT-29 cell line is 71 (Kondoh et al., 1993; Guildbaud 
et al., 2001).  This cell line is widely used in the pharmaceutical industry to screen for 
new anti-colon cancer drugs. 
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1.7.1 Treatment for Colon Cancer 
The methods for treating colon cancer patients are based upon the level to which the 
tumour has progressed in the tissue, which is called staging (Stein et al., 2011).  Some 
patients might need surgery to remove the diseased segment of the colon, followed by 
radiotherapy or chemotherapy.  For stage 1, cancer that has not spread, surgery is the 
treatment of choice.  Stage 1 colon cancer may be treated by removing the cancer tissue 
by performing a colonoscopy (Rex et al., 2006).  In fact, surgery may be the only 
treatment necessary for patient with stage 1 or 2 colon cancer. However, some patients 
with stage 2 cancer may elect to receive chemotherapy (Benson et al., 2004).  More 
extensive surgery is needed for stages 3 and 4 cancers to remove the part of the colon that 
is cancerous.  Following surgery, almost all patients with stage 3 colon cancer receive 
adjuvant chemotherapy (such as topoisomerase I inhibitors and alkylating agents or 
irradiation) for 6 to 8 months (Schrag et al., 2001; Watanabe et al., 2001).  Chemotherapy 
is also used to prolong survival in patients with stage 4 colon cancer.  A variety of 
chemotherapeutic drugs have been tested and used in chemotherapy treatment for colon 
cancer.  One of the most common and beneficial chemotherapeutic drugs used for colon 
cancer is camptothecin and its derivatives, as the overall drug toxicity is low, which 
allows for repeated courses of treatment (Giovanella et al., 1989).   
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Figure 2. A model of the steps of checkpoint adaptation in human cancer cells 
treated with a cytotoxic concentration of genotoxic agents (from Kubara et al., 2012, 
used with permission).  Proliferating colon carcinoma cells arrest in the G2-phase of the 
cell cycle after experiencing a genotoxic event.  By the process of checkpoint adaptation, 
cells enter mitosis.  The majority of cells will die (large arrow), but a small number of 
cells will survive (small arrow), possibly with changes to their genome.   
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1.7.2 Checkpoint Adaptation in Colon Cancer  
HT-29 cell model for checkpoint adaptation was first used by Kubara et al. 
(2012).  This study demonstrated that HT-29 cells, following the treatment with 25 nM 
CPT, recruited histone γ-H2AX (indicating damaged DNA).  Cells that have damaged 
DNA phosphorylate checkpoint kinase 1 (Chk1), which is an indicator of the activation of 
the DNA damage checkpoint.  An analysis of treated cells by flow cytometry showed that 
cells arrested in the G2-phase of the cell cycle.  Furthermore, Western blotting showed 
that cells contained high levels of cyclin B protein and high levels of tyrosine 
phosphorylated Cdk1.  These data demonstrated that the cells had arrested in the cell 
cycle due to damaged DNA induced by CPT, the first criterion of the checkpoint 
adaptation process.  By 48 hours after treatment, many HT-29 cells had entered mitosis.  
These cells had a rounded morphology that was distinct from cells in interphase, and 
presence of phospho-ser10 histone H3.  Importantly, cells in mitosis retained intense 
histone γ−H2AX staining and had very poorly organized mitotic chromosome structures.  
Furthermore, it was reported that the cells that entered into mitosis with damaged DNA 
contained dephosphorylated Ser345-Chk1, indicating a relationship between Chk1 
dephosphorylation and checkpoint adaptation.  Finally, the ability of HT-29 cells to arrest 
in mitosis provided an experimental means to detect and collect cells that had undergone 
checkpoint adaptation (Gascoigne and Taylor, 2008).  
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1.8   Micronuclei 
 A micronucleus appears as a small membrane-bound nucleus that forms due to the 
improper incorporation of acentric fragments or chromosomes into daughter nuclei during 
cell division (Fenech et al., 2011).  Acentric chromosome fragments or whole 
chromosomes fail to be included in the daughter nuclei during mitosis due to improper 
attachment with the spindle during the segregation process.  These displaced 
chromosomes or chromosome fragments are eventually enclosed by a nuclear membrane 
that appears to be morphologically similar to nuclei, except for their smaller size. 
 The presence of micronuclei in cells is commonly used as evidence of mutations 
caused by damaged DNA (Hovhannisyan et al., 2009).  Genomic change acquired in 
micronuclei might contribute to cancer development (Crasta et al., 2012).  Micronuclei 
can also contribute to the formation of DNA breakage and chromothripsis (Crasta et al., 
2012).  One feature of micronuclei is that they likely originate only from cells that have 
undergone mitosis (Luzhna et al., 2013).  Therefore, it is possible that a relationship 
exists between the presence of micronuclei and checkpoint adaptation.  This notion is 
supported by the recent advancements in the study of chromosome damage, or 
chromothripsis.   
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1.9   Chromothripsis     
The word chromothripsis is derived from the Greek terms chromos for color and 
later chromosome, and thripsis for shattering into pieces (Stephens et al., 2011).   
Chromothripsis is a phenomenon by which numerous chromosomal rearrangements occur 
in cells in a short time (Stephens et al., 2011; Hübner et al., 2009).  The majority of 
chromothripsis events are believed to occur in one catastrophic event.  The shattering 
event usually occurs when chromosomes condense into mitotic chromosomes.  A 
chromosome or chromosomal region is broken into tens to hundreds of pieces and then 
rejoined by the DNA repair pathways in a patchwork of genomic fragments.  These new 
chromosomes do not have the original order of the progenitor chromosome(s) (Stephens 
et al., 2011; Forment et al., 2012).  The chromothripsis hypothesis and its implications for 
cancer development were first described by Stephens et al. (2011).   
 There are three distinguishing features of chromothripsis: 
1. The presence of significant numbers of complex rearrangements in 
localized regions of one chromosome or chromosome arm; 
2. Low copy number states (normally between one or two) of the genome 
throughout the rearranged region; and  
3. The conservation of heterozygosity. 
These characteristics have major significance for interpreting how and when 
chromothripsis originates.  First, rearrangements in localized chromosomal regions 
suggest that the condensation of chromosomes is important for the occurrence of 
chromothripsis, such as during mitosis (Forment et al., 2012).  Next, the number of copy  
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Figure 3. A simplified model for the chromothripsis.  Chromothripsis can be 
generated by one catastrophic event in which the chromosome shatters into tens to 
hundreds of pieces. Rearrangements occur by rejoining the pieces together by the 
DNA repair pathways in a mosaic patchwork of genomic fragments, however some 
pieces are lost in the cell.  These new chromosomes do not contain the complete, 
original order that was present in the progenitor chromosomes.  
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number states (normally between one or two, occasionally three) across the 
chromothriptic regions demonstrates that such rearrangements occur within a short time 
(Maher et al., 2012; Forment et al., 2012; Korbel and Campbell, 2013).  If the 
rearrangements had occurred gradually over time, the copy number would eventually 
increase with the number of detected breakpoints, and this has not been observed 
(Forment et al., 2012).  Finally, the alternation of segments retaining heterozygosity with 
others presenting loss of heterozygosity (LOH) in chromothriptic regions suggests that 
the chromosomal rearrangements occur early in cancer cell development. Retention of 
heterozygosity in ‘patches’ throughout a chromothriptic region is difficult to explain by 
progressive rearrangement mechanisms, because once heterozygosity is lost, it cannot 
usually be regained. This adds support to the idea that chromothripsis generally occurs in 
one catastrophic event and is not an ongoing process.  This view contrasts with that of 
accumulating simple mutations over time, as described earlier for colon cancer.   
 
 
1.10     Overview of Thesis 
Cancer patients are frequently treated with cytotoxic agents that ultimately target 
and damage DNA. Cancer cells with damaged DNA initiate a series of biochemical steps 
that enable them to detect the damaged DNA and respond to it.  One of the late events in 
these steps is checkpoint adaptation, a process in which cells enter into mitosis despite the 
presence of damaged DNA.  Checkpoint adaptation was first demonstrated in human 
cancer cells in 2006, following treatment with radiation (Syljuåsen et al., 2006).  
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Although the majority of cells that undergo checkpoint adaptation die, a small percentage 
of them are able to survive and continue to divide with damaged DNA.  The outcome for 
the cells that survive checkpoint adaptation is unknown.  
In this thesis, I have examined HT-29 cells that survived checkpoint adaptation 
after treatment with CPT to provide insight into the possibility of genomic change caused 
by checkpoint adaptation.  This will provide valuable information about the significance 
of checkpoint adaptation in HT-29 cells.   
 
 
1.10.1  Hypothesis  
 Our hypothesis is that human colon cancer cells that survive checkpoint 
adaptation acquire changes in the organization of their genome.  To test this hypothesis, I 
will perform experiments to achieve three research objectives.   
  
 
1.10.2   Research Objectives 
I will use the HT-29 cell culture model of checkpoint adaptation to do the 
following:  
 
1. Assess the percentage of cells that survive checkpoint adaptation using 
defined conditions. 
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2. Examine the chromosomes of the survival cells before, during and 
after a genotoxic treatment. 
 
3. Determine if cells that survive checkpoint adaptation contain damaged 
DNA. 
 
By addressing these objectives, I intend to provide insight in the role of checkpoint 
adaptation in genomic change after genotoxic treatment.  
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Chapter 2 
2.     Materials and Methods 
2.1      Cell Culture 
 
The human cell line HT-29 was obtained from the American Type Culture 
Collection (ATCC).  HT-29 cells were maintained in RPMI 1640 (Invitrogen) medium 
supplemented with 10% decomplemented fetal calf serum (PAA Laboratories, Etobicoke, 
Ontario), 2 mM L-glutamine (Invitrogen), and 10 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), pH 7.4. Cells were grown at 37oC in 5% CO2 and media 
were changed every second or third day.  Typically, HT-29 cells were plated at 400,000 
cells/25 cm2 flask and cultivated for 48 hours prior to treatment.  The compound 
camptothecin (CPT) (Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) to a 
concentration of 10 µM and stored at -20oC until further use.  In experiments where we 
used non-treated cells, cultures were treated with an equivalent amount of DMSO to 
control for the solvent used to carry CPT.  
 
 
2.2     Mechanical Shake-off 
HT-29 cells were plated at 400,000 cells/25 cm2 flask and cultivated for 48 hours 
prior to treatment with compounds.  We incubated these cells with a pharmacologically 
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relevant and cytotoxic concentration of CPT (25 nM).  This concentration is higher than 
the IC50 of CPT for HT-29 and within the range of serum levels of treated patients 
(Rivory et al., 1997).  At the desired time after treatment, culture medium was replaced 
with sterile phosphate buffered saline (PBS 1X; 137 mM sodium chloride (NaCl) (BDH 
Chemicals), 2.7 mM potassium chloride (KCl) (BDH Chemicals), 12 mM disodium 
phosphate (Na2HPO4) (Sigma-Aldrich), 1.8 mM monopotassium phosphate (KH2PO4) 
(Millipore), and distilled H2O) to rinse the flask.  PBS was removed by aspiration to 
eliminate the dead cells in suspension.  A small volume of RPMI (40 µL/cm2) was added 
in the flask and the flask was tapped on all sides with medium force until rounded cells 
were released. 
 
 
2.3     Light Microscopy 
Images were taken with an Infinity 1.5 camera powered by Infinity Capture 
(Lumenera Corporation) software on an Olympus IX41 inverted microscope. Live cells 
were detected by dye exclusion with Trypan Blue 0.4% solution (Amresco) (a 1:1 ratio 
with a sample of cells from culture and Trypan Blue solution) to determine cell viability.  
Dead cells appeared blue and viable cells appeared clear with this dye when observed 
under by microscopy at 200 x magnification. The percentage of live cells was quantified 
within a population using a hemocytometer. 
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2.4     Survival Assay  
 HT-29 cells were plated at 400,000 cells/25 cm2 flask and cultivated for 48 hours 
prior to treatment with compounds.  At desired times after treatment, culture medium was 
replaced with a small volume of RPMI (40 µL/cm2), and flasks were tapped on all sides 
with medium force until rounded cells were released.  Collected rounded cells were 
counted using a hemocytometer and cell viability was confirmed by vital dye exclusion. 
Cells were re-plated in a 25 cm2 flask and placed in the incubator at 37oC until they 
formed sufficiently large colonies (approximately 10 to 12 days).  At desired times, cells 
were collected by trypsinization.  Cells were counted again using a hemocytometer to 
determine the number of cells surviving.  
 The number of surviving cells was estimated using the following formula: N0 = 10 
{logNT-(log2/tg)T}
, where NT = number of cells collected at the end of the survival assay, N0 = 
number of cells that were able to proliferate (i.e., survival cells), tg = generation time in 
hours (for HT-29 cells, tg= 31 hours), and T = time of culture in hours.  Then, the 
percentage of survival cells was counted using the following formula: P = (N0 / N) × 100, 
where N = number of cells placed in the flask at the beginning of the survival assay 
(Leibovitz and Mazur, 1977).  Experiments were repeated at least three times. 
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2.5     Clonogenic Assay  
The method of clonogenic assay was performed as described by Franken et al. 
(2006) with some modifications.  HT-29 cells were plated at 400,000 cells/25 cm2 flask 
and cultivated for 48 hours prior to treatment with compounds.  At the desired time after 
treatment, culture medium was replaced with a small volume of RPMI (40 µL/cm2), and 
cells were collected by mechanical shake-off.  Collected rounded cells were counted 
using a hemocytometer.   
A suspension of 104 cells/ml was prepared and either 5x103, 1x104, or 2x104 cells 
were cultivated in duplicate wells in 6-well plate for 14 days.  The colonies typically 
contain at least 50 cells to represent viable cells.  At desired times, cells were fixed and 
stained using a mixture of 6.0% glutaraldehyde and 0.5% crystal violet for 30 minutes at 
room temperature.  Cells were rinsed with water.  The plate with cell colonies was left to 
dry in normal air at room temperature.  Non-treated cells were also analyzed separately 
for plating efficiency by clonogenic assay.  For plating efficiency, a suspension of non-
treated HT-29 cells at 2.0x103cells/ml was prepared and 50, 100, or 200 cells were 
cultivated in duplicate wells for 14 days.  Colonies were counted using ImageJ software 
to determine the number of cells surviving. 
The plating efficiency (PE) of the non-treated cells was determined by the 
following formula: PE = (number of colonies formed/ number of cells seeded) x 100%.  
The surviving fraction (SF) was counted using the following formula: SF= number of 
colonies formed after treatment/ (number of cells seeded x PE).  Experiments were 
repeated at least twice. 
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2.6     Immunofluorescence Microscopy 
 Cells were plated on glass coverslips for 48 hours before treatment.  Cells 
collected by mechanical shake-off were attached to glass coverslips coated with poly-L-
lysine (Invitrogen).  At desired times cells were fixed in 3% formaldehyde for 20 minutes 
at room temperature and permeabilized for 5 minutes in 0.2% Triton X-100.  Cells were 
incubated with anti-histone γ-H2AX (1:300, No. 05-636, Millipore).  The secondary 
antibody Alexa488 (1:400, Molecular Probes/Invitrogen) for anti-histone γ-H2AX was 
added for 2 hours.  Nuclei were stained with 300 nM 4'6-diamidino-2-phenylindole 
(DAPI) in PBS for 15 minutes prior to mounting. Cells were observed on a Zeiss 
microscope operated by Axiovision 3.1 software.  Images were collected by Zeiss MR 
camera within the linear dynamic range. Images were prepared for presentation using 
identical parameters with Adobe Photoshop CS3 10.0 software.  Experiments were 
repeated at least three times.  On average, 250 cells were analyzed per experimental group 
per replicate.   
 
 
2.7     Alkaline Comet Assay  
 Cells were plated at 350,000 cells/ 25 cm2 flask for 48 hours and were maintained 
in RPMI 1640 (Invitrogen) medium supplemented with 10% decomplemented fetal calf 
serum (PAA Laboratories, Etobicoke, Ontario), 2 mM L-glutamine (Invitrogen), and 10 
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mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.4 before 
treatment. Cells were grown at 37oC in 5% CO2.  Rounded mitotic cells were collected by 
mechanical shake-off and were used in comet assay analysis for DNA damage.  Survival 
cells were also analyzed separately for DNA damage using the comet assay.  These cells 
were compared to those that are not treated with CPT.  
The method of alkaline comet assay was performed as described by Tice and 
Vasquez (1999) with some modifications.  Partly frosted microscope slides were coated 
with 1% regular agarose (Bio Basic Inc) and allowed to dry for 2 to 3 minutes at room 
temperature.  For next layer, approximately 40,000 cells were mixed with 2% low 
melting point agarose (LMPA; MJS BioLynx) and placed onto a pre-coated slide and 
immediately covered with a coverslip for 10 to 15 minutes.  The coverslip was then 
removed from the initial agarose layer. Once set, 1% regular agarose was placed as a final 
layer on top of the cell-LMPA mix layer and again covered immediately with a coverslip.  
The final coverslip was removed once the gel had set. At this point the remainder of the 
assay was performed using indirect light. 
Next, the slides were placed in the freshly made lysis solution (2.5 M sodium 
chloride (NaCl) (BDH Chemicals), 100 mM EDTA (pH 8.0) (BDH Chemicals), 1% 
sarkosyl (Sigma-Aldrich), 10 mM Tris-HCl (pH 8.0) (EMD), 10% DMSO (Bio Basic Inc), 
10% Triton X-100 (EMD)) on a bed of ice for a minimum of 1 hour.  After 1 hour, the 
slides were washed with ice-cold PBS for 15 minutes.  Next, the slides were placed gently 
into a horizontal electrophoresis tank filled with cold alkali buffer (0.3 M sodium 
hydroxide (NaOH) (BDH Chemicals) and 1 mM EDTA) for 30 minutes to allow the 
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DNA to denature in the alkali buffer.  The pH of the buffer was >13.  The electrophoresis 
was performed at 22 V (500 mA) for 30 minutes.  Next, the slides were removed and 
rinsed by placing them in ice-cold neutralising buffer (0.5 M Tris-HCl (pH 7.5) (EMD)) 
for 10 minutes followed by ice-cold PBS for 15 minutes. Ethidium bromide (0.1 mg/ml) 
(EtBr) (Sigma-Aldrich) stain was added to each slide to stain the DNA for 15 minutes and 
then washed with dH2O. Stained DNA was analyzed by a Zeiss microscope operated by 
Axiovision 3.1 software.  Images were collected with a Zeiss MR Camera within the 
linear dynamic range.  DNA damage was measured using Comet Score software 
expressed as percent DNA in tail and Olive moment.  Based on our experience and 
published literature, values higher than 20% DNA in the tail were considered as damaged 
cells (Olive et al., 1990). Experiments were repeated at least three times.  Typically, an 
average of 200 cells was analyzed per experimental group per replicate.  
 
 
2.8      Karyotyping 
The method for karyotyping was performed as described by Cassio (2006) with 
some modifications.  Cells were plated at 350,000 cells/25 cm2 flask for 48 hours and 
were maintained in RPMI 1640 (Invitrogen) medium supplemented with 10% 
decomplemented fetal calf serum (PAA Laboratories, Etobicoke, Ontario), 2 mM L-
glutamine (Invitrogen), and 10 mM HEPES, pH 7.4 before treatment. Cells were grown at 
37oC in 5% CO2.  Cells were treated with 25 nM CPT for 48 hours followed by overnight 
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treatment of KaryoMAX colcemid (10 µg/ml) (Cedarlane).  Colcemid was used to 
increase the number of metaphase cells in a population.  Next, freshly prepared hypotonic 
solution (0.075 M KCl (BDH Chemicals) and distilled H2O) was added to the cells for 20 
minutes to make nuclei swell osmotically.  Then, cells were fixed by adding 3:1 methanol 
(Fisher Scientific) and acetic acid (BDH Chemicals) solution and incubated for 30 
minutes with agitation followed by 5 minutes centrifugation at 220 rcf.  Cells were re-
suspended in 0.5 ml fixative.  A drop of the cell suspension was placed on a cold, clean 
glass slide and blown hard to disperse the chromosomes.  The slides were air dried at 
room temperature and stained with 300 nM DAPI (Life Technologies).  Slides were 
analyzed by a Zeiss microscope operated by Axiovision 3.1 software.  Images were 
collected by Zeiss MR Camera within the linear dynamic range.  Survival cells were also 
analyzed for genomic change by performing karyotyping.  These cells were compared to 
those that are not treated with CPT.  Experiments were repeated at least three times.  
Typically, an average of 50 cells was analyzed per experimental group per replicate. 
 
 
2.9     Fluorescence In Situ Hybridization (FISH) Analysis With PNA Probes 
The method for Fluorescence In Situ Hybridization (FISH) was modified from the 
protocol supplied by PNA Bio Inc.  Slides were prepared as described above in the 
Karyotyping section (Section 2.8).  Samples were fixed using formaldehyde fixing 
solution (4% formaldehyde (Ted Pella) in PBS) for 2 minutes followed by RNase solution 
(100 µg/ml RNase A (Sigma-Aldrich) in PBS) and incubated for 20 minutes at 37oC.  
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Mixture of PNA probes (FAM labeled PNA TelC probe (CCCTAACCCTAACCCTAA); 
Alexa488 labeled PNA TelC probe (A488-OO-CCCTAACCCTAACCCTAA); and Cy3 
labeled PNA centromere probe (ATTCGTTGGAAACGGGA) (PNA Bio)) and 
hybridization buffer (20 mM Tris, pH 7.4, 60% formamide (Sigma-Aldrich), 0.1 µg/ml 
UltraPure salmon sperm DNA solution (Life Technologies), and distilled water, final pH 
7.4) was added to the slide followed by incubation at 85oC for 10 minutes.  Next, the slide 
was immersed in a wash solution (2X SSC (distilled water, NaCl (BDH chemicals), 
sodium citrate (Sigma-Aldrich), HCl (Fisher Scientific) and 0.1% Tween-20 (Sigma-
Aldrich)) at 55-60oC for 10 minutes.  The slide was stained with 300 nM DAPI (Life 
Technologies) solution for 10 minutes followed by two washes with 1x SSC and 2x SSC. 
Chromosomes were analyzed by a Zeiss microscope operated by Axiovision 3.1 software.  
Images were collected by Zeiss MR camera within the linear dynamic range.  Survival 
cells were also analyzed separately for genomic rearrangement by performing FISH 
analysis.  These chromosomes were compared to those that were not treated with CPT.  
Experiments were repeated at least three times. Typically, an average of 50 cells was 
analyzed per experimental group per replicate. 
 
 
2.10  Statistical Analysis 
 Statistical analysis was performed by the Student’s t-test. Data are presented as 
mean ± standard deviation (SD). A probability level of P < 0.05 was considered 
significant.  
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Chapter 3 
3.   Results 
3.1   HT-29 Cells Treated with Camptothecin (CPT) Undergo Checkpoint 
Adaptation 
 Previously, Kubara et al. (2012) showed that HT-29 cells undergo checkpoint 
adaptation when treated with pharmacologically relevant concentrations of CPT.  In this 
process, cells with damaged DNA become arrested in the G2 phase of the cell cycle.  
However, nearly all cells escape the DNA damage checkpoint and enter mitosis.   These 
cells fulfil the three features that define checkpoint adaptation: an arrest in the cell cycle 
due to damaged DNA, overcoming this arrest, and then entering into mitosis despite the 
presence of damaged DNA (Toczyski et al., 1997).  The first step in my thesis was to set 
up this assay of checkpoint adaptation so that I could collect mitotic cells.  These cells 
would allow me to test the hypothesis that cells which survive checkpoint adaptation will 
have changes in their genome.  To address this hypothesis, I first attempted to answer this 
question: What is the percentage of cells that survive checkpoint adaptation?   
 At 24 hours after CPT treatment, nearly all cells were flat and strongly adherent.  
Rounded cells, which were weakly adherent, were present by 48 hours of CPT treatment 
(Figure 4A).  Rounded morphology is one of the defining features of mitotic cells, 
especially those that have undergone checkpoint adaptation.  These rounded mitotic cells 
were separated by mechanical shake-off (Figure 4C) from the flattened interphase  
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Figure 4.  HT-29 cells treated with camptothecin (CPT) undergo checkpoint 
adaptation.   
 
HT-29 cells entered mitosis by 48 hours after treatment with CPT.  We used 
mechanical shake-off to isolate cells that have undergone checkpoint adaptation 
(mitotic cells) from interphase cells.  Images were collected by light microscopy. 
A. Cells treated with 25 nM CPT for 48 hours. 
B. Cells remaining on culture dish immediately after mechanical 
shake-off at 48 hours. 
C. Mitotic cells collected by mechanical shake-off. 
D. The culture (B) 2 hours after performing a mechanical shake-off in 
which new mitotic cells (rounded cells) appear. 
Scale bar = 100 µm. 
 
 
 40 
 
cells.  The vital dye exclusion technique was used to test if the CPT treated, rounded cells 
were alive or not.  In this assay, live cells are able to exclude a vital dye, trypan blue.  We 
confirmed that 95% of the HT-29 rounded mitotic cells were alive, which was consistent 
with previous results from my laboratory (Kubara et al., 2012).  The remaining adherent 
cells were re-cultivated (Figure 4B).  We selected a time of two hours at which we 
observed by light microscopy that new rounded cells appeared from the flattened cells 
indicating confirming that checkpoint adaptation is a continuous process (Figure 4D).  
The result of this experiment confirmed that HT-29 cells enter into mitosis following 48 
hours of 25 nM CPT treatment.  By establishing this experimental system we would be 
able to further investigate the fate of human cancer cells that undergo checkpoint 
adaptation. 
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3.2   Cells that Undergo Checkpoint Adaptation are Able to Survive    
The next step was to determine if the rounded mitotic HT-29 cells were able to 
survive and continue to divide.  If the cells were able to survive, it would be possible that 
they have changed their genome because they originated from a population of cells with 
damaged DNA.  We have used several approaches to determine the number of cells that 
survive checkpoint adaptation: the clonogenic assay and cell counting at various times 
(survival assay).   
 We investigated the number of cells that survive checkpoint adaptation by the 
clonogenic assay.  Mitotic cells were first collected from non-treated HT-29 cells to 
measure the plating efficiency of the cell line.  This efficiency value was needed to 
calculate the number of cells surviving under standard culture conditions, without 
treatment. For this purpose, 50, 100, or 200 non-treated HT-29 cells were cultivated in 
duplicate cultures in a 6 well plate (Figure 5).  After calculation, we found that the plating 
efficiency of the HT-29 cells was 53%, consistent with that of previously published 
results (Ware et al., 2007).   
 In preliminary experiments we learned that we needed to inoculate the cultures 
with many more cells when using the treated sample to accommodate the cell mortality 
from treatment, which was coherent with the goal of finding survivor cells.  Mitotic cells 
were collected from the 48 hour CPT treated culture, and approximately either 5 x103, 1 
x104, or 2 x104 cells were cultivated in duplicate wells in a 6-well plate (Figure 6).  The 
colonies of at least 50 cells were considered viable.  Colonies were counted using ImageJ 
software and then calculated to determine the number of cells surviving.  The clonogenic  
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Figure 5. The clonogenic assay was performed on non-treated HT-29 colon cancer 
cells to measure plating efficiency. An image of a 6 well plate after staining with crystal 
violet is shown. 
 
 A and B. 200 non-treated HT-29 cells were cultivated. 
 C and D. 100 non-treated HT-29 cells were cultivated. 
 E and F.  50 non-treated HT-29 cells were cultivated. 
Scale bar = 3.5 cm. 
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Figure 6. The clonogenic assay was performed on CPT treated, mitotic HT-29 
cells to quantify the number of cells that survive checkpoint adaptation.  An 
image of a 6 well plate after staining with crystal violet is shown. 
 
Cells were cultivated by a dilution series in a six-well plate: 
 A and B. 2 x 104 CPT treated HT-29 cells were cultivated. 
 C and D. 1 x 104 CPT treated HT-29 cells were cultivated. 
 E and F.  5 x 103 CPT treated HT-29 cells were cultivated. 
Scale bar = 3.5 cm. 
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Figure 7.  Images taken by light microscopy of non-treated and CPT treated 
HT-29 cells collected by mechanical shake-off and re-cultivated.  Cells counts 
were performed to estimate the number of cells that survive CPT treatment.   
 
A.  HT-29 non-treated, mitotic cells after mechanical shake-off.  
B.  Mitotic cells collected by mechanical shake-off after treatment with 25 nM 
CPT for 48 hours. 
C.  Non-treated cells, 12 days after mechanical shake-off.  
D.  CPT treated cells 12 days after mechanical shake-off (CAS cells).      
Scale bar = 100 µm. 
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assay revealed that 1 +/- 0.3% of the CPT treated, mitotic cells retained the capacity to 
produce colonies.   
 We then approached the cell counting experiment by a second method using direct 
counting with a hemocytometer.  In this approach, HT-29 cells were either treated with 25 
nM CPT or were untreated, as described in the previous section.  At 48 hours, rounded 
cells were collected by mechanical shake-off, counted, and re-plated as new cultures and 
then counted again at 12 days post re-plating.  Images of cells collected by mechanical 
shake-off and of cultures that arose from these two populations were taken (Figure 7A 
and B), revealing mitotic cells from both non-treated and treated populations.  By 12 
days, the non-treated cells culture contained many large groups of cells (Figure 7C) 
whereas the CPT treated mitotic cells produced few groups that colonized the culture dish 
(Figure 7D).  At 12 days both the non-treated and treated cells were collected by 
trypsinization and counted using a hemocytometer. We found that on average, in three 
experiments, 3 +/- 0.9% (n = 1.8 x 105) of the cells that underwent checkpoint adaptation 
were able to survive and proliferate.  Thus, the two approaches, clonogenic assay and 
direct counting, gave similar results in that a small percentage of cells that enter 
checkpoint adaptation can survive.  From now on, we will call the survival cells CAS 
cells (Checkpoint Adaptation Survival cells).  These results indicated that we could now 
examine CAS cells for differences in their genome relative to non-treated cells.   
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3.3    Ninety Percent of the CAS HT-29 Cells are Negative for Histone γ-H2AX 
 Having established that 1-3% of HT-29 cells that undergo checkpoint adaptation 
are able to survive, we wanted to know if there were changes in their genome relative to 
non-treated cells.  This question was important because the agent that we used to induce 
checkpoint adaptation was the genotoxic compound CPT (Goldwasser et al., 1995).  
Therefore, we used several approaches to test cells for damaged DNA.  In the first 
approach, we used immunofluorescence microscopy to look for histone γ-H2AX, a 
protein that is used by cells to signal and repair damaged DNA. 
For this experiment we set up three populations of HT-29 cells:  
1. Non-treated cells as a negative control,  
2. Cells treated with 25 nM CPT for 48 hours, 
3. CAS cells, collected at 10 days post mechanical shake-off.   
Cells were grown on coverslips under the above conditions, then fixed and stained with 
DAPI to mark DNA, and stained with histone γ-H2AX antibodies to mark damaged DNA 
if present.  Images were collected with CCD camera set so that signals were within the 
linear range of detection (Cahuzac et al., 2010).  We found that 3 +/- 0.7% (n = 750) of 
the non-treated HT-29 cells displayed histone γ-H2AX signals, as expected, (Figure 8D) 
even though several hundred nuclei were inspected by DAPI staining (Figure 8A).  By 
contrast, HT-29 cells treated with CPT for 48 hours showed distinctive large nuclei 
(Figure 8B) by DAPI staining, and 94 +/- 2.1% (n = 750), P < 0.05  (where P = 0.04) of 
CPT treated cells displayed histone γ-H2AX pan-nuclear staining, with many foci, typical 
for this treatment in HT-29 cells (Figure 8E) (Furuta et al., 2003), as previously reported  
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Figure 8. Analysis of non-treated and CAS cells by immunofluorescence 
microscopy for histone γ-H2AX staining. 
HT-29 cells were either non-treated or treated with CPT.  After 48 hours, cells 
were collected by mechanical shake-off and then re-plated, and analyzed by 
damaged DNA by immunofluorescence microscopy.   
 
A and D.  Non-treated HT-29 cells 
 B and E.  Cells treated with 25 nM CPT for 48 hours. 
C and F.  CAS cells collected by mechanical shake-off and cultivated for 
12 days. 
Cells were stained with DAPI (top) or histone γ-H2AX antibodies (bottom).  Scale 
bar = 25 µm. 
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Figure 9.  Analysis of non-treated and CAS cells by immunofluorescence 
microscopy for histone γ-H2AX staining after a second treatment with CPT. 
 
 A and C.  CPT treated cells at 48 hours post-treatment (positive control).  
 B and D.  CAS cells were retreated with CPT (25 nM) for 48 hours. 
Cells were stained with DAPI (top), histone γ-H2AX antibodies (bottom).  Scale 
bar = 25 µm. 
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(Kubara et al., 2012).  However, immunofluorescence microscopy revealed that the 
nuclei of CAS cells were the size of the nuclei of non-treated cells (Figure 8C), and few 
of the nuclei of CAS cells were positive for histone γ-H2AX.  This experiment, which 
was repeated three times, indicated that approximately 90 +/- 1.5% (n = 750), P < 0.05 
(where P = 0.01) of the CAS cells no longer signaled damaged DNA (compared to the 
cells treated with CPT for 48 hours), although they originated from a population of cells 
with damaged DNA (Figure 8F).   
 Given that the CAS cells originated from CPT treated cells, we decided to ask if 
they were capable of signalling DNA damage, i.e. does the histone γ-H2AX pathway still 
function?  To test this, we re-treated the CAS cells with 25 nM CPT for 48 hours then 
fixed and stained them for histone γ-H2AX to detect damaged DNA by microscopy.  
Upon re-treatment with CPT, an average of 45 +/- 4% (n = 750), of the CAS cells were 
histone γ-H2AX positive (Figure 9D), whereas control HT-29 cells were 94 +/- 2.1% (n = 
750) (Figure 9C) positive after treatment (the difference is statistically significant at P < 
0.05, where P = 0.03).  These results provided our first evidence that some CAS cells 
might have a different genome from the original HT-29 population. 
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3.4   CAS Cells have Damaged DNA as Demonstrated by the Alkaline Comet Assay 
 I used the alkaline comet assay to measure damaged DNA.  A comet assay is 
based on the principle that short fragments of DNA will migrate faster than the long 
fragments in an electric field (Collins et al., 1997).  In cells, undamaged DNA is intact 
and condensed in the nucleus; however, when damaged, the DNA breaks into pieces.  The 
comet assay has the potential to measure damaged DNA in individual cells.  In my 
project, the alkaline comet assay provided an opportunity to measure damaged DNA in 
cells that had undergone checkpoint adaptation and to complement studies in which the 
histone γ-H2AX signal was used to identify cells with damaged DNA.  By a preliminary 
test, I provided an illustration of alkaline comet assay on CPT treated HT-29 cells (Figure 
10).  The appearance of the damaged DNA on the image created a comet like shape 
(Figure 10C).  A bright and elongated tail in the gel was caused the presence of DNA 
fragments and represented intense DNA damage.  The Comet Score software enabled one 
to quantify the overall signal strength and the relative amount of the fluorescence of the 
DNA strands (Figure 10B and D).  A high signal indicated more damaged DNA as they 
move through the electric field (Figure 10C and D).  No comet could be measured in non-
treated cells as no fluorescence signal was detected outside of the nucleus (Figure 10A 
and B).   
 We explored the status of the DNA of the CAS cells by the alkaline comet assay 
because it was perplexing that 45% of the CAS cells no longer signaled damaged DNA 
after re-treatment with 25 nM CPT.  For this experiment, we set up six populations of 
HT-29 cells: 
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Figure 10. Levels of DNA damage after exposure to CPT evaluated by alkaline 
comet assay. HT-29 cells were either not treated (top row) or treated with 25 nM 
CPT for 48 hours (bottom row).  Cells were collected and then processed by the 
alkaline comet assay to score them for damaged DNA using fluorescence 
microscopy and comet analysis software.   
 
A. Fluorescence microscopy image of cells without CPT treatment (9% DNA in the 
tail, Olive moment = 2.3). 
B. Image A after processing by the Comet Score software. The colour codes 
represent different amounts of fluorescence intensity from purple (highest) to 
red (lowest).   
C. Fluorescence microscopy image of cells treated with 25 nM CPT for 48 hours 
(50% DNA in the tail, Olive moment = 44.3). 
D. Image C after processing by the Comet Score software. The colour codes 
represent different amounts of fluorescence intensity from purple (highest) to 
red (lowest).  Scale bar = 100 µm. 
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Figure 11. Analysis of the DNA of HT-29 cells with and without CPT 
treatment and in CAS cells by the alkaline comet assay.  HT-29 cells either 
non-treated or treated with CPT were collected by mechanical shake-off at 48 
hours post treatment.  Cells were then re-plated and cultivated for 10 days.  At 
each treatment, cells were prepared for analysis by the alkaline comet assay.  
Image of samples from the alkaline comet assay were taken by fluorescence 
microscopy.  This experiment was performed three times.   
A.  Non-treated interphase cells.   
B.  Non-treated mitotic cells collected by mechanical shake-off.   
C.  Mock CAS cells. 
D.  Interphase cells treated 48 hours with 25 nM CPT.  
E.  Mitotic cells treated 48 hours with 25 nM CPT collected by mechanical shake-
off.   
F.  CAS cells collected at 10 days. Scale bar = 100 µm. 
G. An average of 200 cells was analyzed per experimental group per replicate. 
The results were statistically significant at P < 0.05 using Student’s t-test between 
each paired group of non-treated and CPT treated. 
G 
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Figure 12. Olive tail moment determined by the alkaline comet assay of HT-29 cells 
either non-treated or treated with CPT and collected under various conditions. This 
experiment was performed three times.  An average of 200 cells was analyzed per 
experimental group per replicate.  The error bars show standard deviation. The results 
were statistically significant at P < 0.05 using Student’s t-test between each paired group 
of non-treated and CPT treated. 
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1. Non-treated interphase cells, 
2. Non-treated mitotic cells,  
3. Non-treated mock CAS cells,  
4. 25 nM CPT treated interphase cells for 48 hours, 
5. 25 nM CPT treated mitotic cells for 48 hours, and  
6. CAS cells collected at 10 days after mechanical shake-off.  
 The alkaline comet assay was performed to quantify the DNA damage with the 
percentage DNA in the tail and Olive moment (fraction of DNA in tail together with 
length of comet).  The absence of a comet tail in the non-treated cells of each type 
(interphase, mitotic, and mock survival) (Figure 11A, B and C) confirmed that they 
contained little damaged DNA, as expected.  By contrast, 68 +/- 8.3% (n = 600; P = 
0.003) of the interphase and 82 +/- 4.7% (n = 600; P = 0.0001) of the mitotic HT-29 cells 
treated with CPT for 48 hours displayed comets indicating that this population had 
damaged DNA (Figure 11D and E).  Strikingly, the alkaline comet assay revealed that 73 
+/- 2.5% (n = 600; P = 0.001) of the CAS cells displayed comets (Figure 11F), suggesting 
that their genome contained damaged DNA.  An increase in Olive moment also indicated 
a higher amount of DNA damage in CPT treated interphase cells and mitotic cells, and 
CAS cells at 17.2 +/- 3.2 (n = 600; P = 0.006), 22.6 +/- 3.1 (n = 600; P = 0.007), and 20.3 
+/- 1.3 (n = 600; P = 0.002) respectively, compared to the same non-treated cells, which 
had an Olive moment of 3.5 +/- 0.4, 6.3 +/- 5.8, and 3.0 +/- 0.7 (n = 600) respectively 
(Figure 12).  The results were statistically significant at P < 0.05 using Student’s t-test 
between each paired group of non-treated and CPT treated cells.  This result contrasted 
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with that of the staining with histone γ-H2AX antibodies, which had indicated that 90% 
of the culture did not signal damaged DNA.  This result indicates that CAS cells contain 
damaged DNA and somehow are able to either tolerate it, or modify the pathways that 
signal it.   
 
 
3.5    Karyotype Analysis Reveals a Shattered Chromosome Phenotype 
 We found that a small percentage of CPT treated cells were able to survive 
checkpoint adaptation to become CAS cells.  These cells showed a mixed response to 
subsequent CPT treatment as measured by histone γ- H2AX staining and a positive score 
in the alkaline comet assay.  It is likely that they have changes in the organization of their 
genome and might be genetically different from parent cells prior to treatment.  
 We then examined the nuclei of CAS cells by several different approaches to 
determine if changes had occurred during the process of checkpoint adaptation and 
survival.  For this experiment, HT-29 cells were treated with 25 nM CPT for 48 hours.  
Following treatment, mitotic cells were collected by mechanical shake-off and cultivated 
for 10 days.  We followed the same procedure for the non-treated culture.  We first 
examined CAS cells by light microscopy for the formation of micronuclei.  Micronuclei 
are used as evidence of chromosome and/or genomic changes (Nakada et al., 2006, 
Nitiss, 2009; Luzhna et al., 2013).  In this case, we defined cells as being positive for 
micronuclei when they had more than one nuclear structure. We observed that 2 +/- 0.6%, 
of the CAS cells, when collected at 10-12 days, had micronuclei, whereas 1 +/- 0.1%  
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Figure 13. Cells that survive mitosis following treatment with CPT acquire 
micronuclei.   
 
 A.  Non-treated cells 6 days after mechanical shake-off. 
B, C and D. Mitotic cells collected by mechanical shake-off after 
treatment with 25 nM CPT for 48 hours and cultivated for 6 days.  Arrows 
indicate nuclei. Scale bar = 100 µm. 
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micronuclei was observed in non-treated, parental cells (Figure 13).  Although these 
differences in micronuclei were not significant, they led to new studies about the presence 
of micronuclei at earlier times, which are ongoing in the laboratory.   
 We decided to examine chromosome structure and chromosome number by 
karyotype analysis.  To compare the karyotype of cells that had undergone checkpoint 
adaptation to those of non-treated cells, we prepared four populations of HT-29 cells: 
1. Non-treated cells,  
2. Non-treated mock CAS cells,  
3. Cell treated with 25 nM CPT for 48 hours,  
4. CAS cells, collected at 10 days.   
 Cells from each population were collected and chromosome were isolated and 
observed by microscopy.  Analysis of the non-treated HT-29 cells revealed that they 
contained whole chromosomes with a characteristic shape, as expected (Figure 14A).  By 
contrast, analysis of the cells that were undergoing checkpoint adaptation at 48 hours post 
CPT treatment contained tens to hundreds of chromosome pieces, as if the chromosomes 
had been shattered (Figure 14C).  Images of the CAS cells, which had been treated with 
25 nM CPT and then cultivated for 10 to 12 days, revealed that they contained 
chromosomes that were largely intact, but appeared to be shorter and wider (Figure 14D) 
than those of non-treated HT-29 mock CAS cells (Figure 14B). We found that CAS cells 
contained approximately 35 +/- 13 (n = 150) chromosomes on average whereas non-
treated cells contained 65 +/- 8 (n = 150) chromosomes.  These differences were 
statistically significant at P < 0.05 (where P = 0.01) using Student’s t-test. The typical  
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Figure 14.  Karyotype analysis of CPT treated HT-29 cells reveals a shattered 
chromosome phenotype and changes in chromosome numbers. 
 A. Non-treated cells. 
 B. Mock CAS cells. 
 C. Cells treated with 25 nM CPT for 48 hours.  
 D. CAS cells. Scale bar = 5µm. 
 E. A representation of the average number of chromosomes from three 
experiments in non-treated cells, HT-29 mock CAS cells, or CAS cells, 
respectively.  An average of 50 cells was analyzed per experimental group per 
replicate. The error bars show standard deviation.  * indicates significance based 
on Student’s t-test (P < 0.05).  
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chromosome number of HT-29 cell line is 71 (Kondoh et al., 1993).  The number of 
chromosomes in CAS cells ranged from 18 to 51, whereas the number of chromosomes 
from the non-treated HT-29 cells ranged from 58 to 74.  These data indicated that the 
number of chromosomes per CAS cell was variable within the survivor population.  It 
provided evidence that CAS cells have major changes in the organization of their genome 
and that the genomes varied between survivor cells.   
 
 
3.6   FISH Analysis Reveals Genomic Rearrangement within CAS Cells 
To understand better the level of genomic change in HT-29 CAS cells, we 
performed Fluorescence In Situ Hybridization (FISH) analysis.   FISH analysis can 
provide information about the presence or absence of structural elements that are required 
for chromosomes, such as telomeres or centromeres.  Absence or misplacement of 
telomeres or centromeres in a chromosome would suggest that cells have a rearranged 
genome.  To analyze CAS cells by FISH, we prepared three populations of HT-29 cells: 
1. Non-treated cells,  
2. Cells treated with 25 nM CPT for 48 hours and collected by mechanical 
shake-off, and 
3. CAS cells, collected at 10 days.   
FISH analysis of the non-treated HT-29 cells revealed that their chromosomes had a 
characteristic shape by DAPI staining (Figure 15A), and almost all the chromosomes 
contain centromeres (Figure 15B) and telomeres (Figure 15C) at the correct locations.  In  
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Figure 15.  Chromosomes of non-treated HT-29 cells analyzed by FISH. 
 A. Non-treated cells stained with DAPI to mark whole chromosomes. 
 B. Non-treated cells labeled with the Cy3 centromere probe followed by staining 
with DAPI. 
 C. Non-treated cells labeled with the A488 PNA TelC telomere probe followed by 
staining with DAPI. 
Scale bar = 25 µm. 
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Figure 16.  Chromosomes of HT-29 cells treated with CPT for 48 hours 
analyzed by FISH.  
 A. Cells were treated for 48 hours with CPT, collected by mechanical shake-off 
then stained with DAPI to mark the chromosome. 
 B. Cells were treated for 48 hours with CPT, collected by mechanical shake-off 
then labeled with Cy3 centromere probe followed by staining with DAPI. 
 C. Cells were treated for 48 hours with CPT, collected by mechanical shake-off 
then labeled with A488 PNA TelC telomere probe followed by staining with 
DAPI. 
Scale bar = 25 µm. 
 
 
 
 
 62 
 
 
 
 
  
Figure 17.  Chromosomes of HT-29 CAS cells collected at 10 days after 
treatment with CPT and analyzed by FISH.  
 A. CAS cells stained with DAPI to mark whole chromosomes. 
 B. CAS cells labeled with Cy3 centromere probe followed by staining with DAPI. 
 C. CAS cells labeled with A488 PNA TelC telomere probe followed by staining 
with DAPI. 
Scale bar = 25 µm. 
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Figure 18.  Comparison of the number of centromeres of non-treated HT-29 
cells with CAS cells. 
 A and B. CAS cells were stained with DAPI (A) and labeled with the Cy3 
centromere probe (B). Images were collected by fluorescence microscopy. Scale bar 
= 15 µm. 
C. The number of centromere signals by FISH analysis is represented as a percentage 
of signals from non-treated cells (Normal chromosomes).  Black columns are counts 
from non-treated cells and grey columns are counts from CAS cells.  The counts 
were grouped into four categories:  normal chromosomes (signals within a 
chromosome), more centromeres (those with more than one centromere signal per 
chromosome), less centromeres (those with less than one centromere per 
chromosome in a chromatid), Chromosomes without centromeres.  The error bars 
show standard deviation.   
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Figure 19.  Comparative analysis of telomeres of non-treated HT-29 cells and 
HT-29 CAS cells. 
A. CAS cells were labeled with A488 PNA TelC telomere probe and stained with 
DAPI. The square highlights a chromosome that is missing telomeres and the 
circle represents a chromosome in which the telomere is located a region other 
than the chromosome tip position.  The image is shown as a negative format.  
Scale bar = 15 µm. 
B. The number of telomere signals from FISH analysis is represented as a 
percentage of signals from non-treated cells.  Black columns are counts from non-
treated cells and grey columns are counts from CAS cells.  The counts were 
grouped into three categories:  normal chromosomes (signals at tips of 
chromosomes), signals not at chromosome tips, chromosomes without telomere 
signals. The results were statistically significant at P < 0.05 using Student’s t-test 
between each paired group of non-treated and CAS cells. 
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contrast, mitotic cells collected at 48 hours after CPT treatment showed a shattered 
chromosome pattern that was reminiscent of chromothripsis (Figure 16A).  These cells 
displayed centromeres (Figure 16B) and telomeres (Figure 16C), however, it was not 
possible to describe their position relative to chromosomes because of the shattered 
structures.  We found that mitotic cells collected at 48 hours after CPT treatment 
contained an average of 62 +/- 6 (n = 150) centromeres, which was consistent with our 
values from karyotyping.  By contrast there were 43 +/- 7 (n = 150) centromeres on 
average, in the CAS cells.  These differences were not statistically significant that support 
our observation from karyotype analysis in which the number of chromosomes in the 
CAS cells ranged from 18 to 51.  Almost 96 +/- 3% (n = 150) of the chromosomes in the 
CAS cells contained centromeres (Figure 17B and Figure 18B), as percentage that was 
not statistically different from the non-treated cells.   
 Analysis of telomeres in CAS cells, however, revealed a different pattern.  At least 
one out of four telomeres was missing in about 45 +/- 7% (n = 150; P = 0.02) of the CAS 
cells (Figure 17C and Figure 19A).  Moreover, 28+/- 6.5% (n = 150; P = 0.01) of the 
telomeres in the CAS cells were not located at the ends of the chromosomes (Figure 
19A).  These results were statistically significant at P < 0.05 using Student’s t-test 
between each paired group of non-treated and CAS cells.  In addition to numerical 
changes in chromosome number in CAS cells, there were changes in telomere number or 
in detection of telomeres.  Cells in mitosis with damaged DNA, however, contain 
telomere and centromere signals, but it was not possible to determine how they were 
organized amongst the pieces of DNA in a shattered phenotype.  These observations 
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support that there are genomic rearrangements in the CAS cells that survive checkpoint 
adaptation.   
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Chapter 4 
4.  Discussion 
In this thesis, I described experiments in which we analyzed the DNA of human 
cancer cells that have undergone checkpoint adaptation.  These experiments are important 
because they address a key question in cancer cell biology: how might the genome of 
cancer cells change?  To study this question, I first had to learn one experimental model 
of checkpoint adaptation which was recently published by my laboratory (Kubara et al., 
2012).  By using our model, I was able to collect cells that survive checkpoint adaptation.  
We have examined these cells by techniques including immunofluorescence microscopy, 
the alkaline comet assay, karyotyping, and FISH analysis.  What becomes of the cells that 
survive checkpoint adaptation has not been described previously.  We now provide 
preliminary evidence that the genome may be changed in cells that appear to survive 
checkpoint adaptation.    
 
 
4.1   HT-29 Cells Treated With Camptothecin (CPT) Undergo Checkpoint 
Adaptation 
Checkpoint adaptation is a process that occurs in several different types of cancer 
cells when they are treated with pharmacologically relevant concentrations of genotoxic 
agents (Syljuåsen et al., 2006; Cahuzac et al., 2010; Rezacova et al., 2011; Kubara et al., 
2012).  It is characterized by an arrest in the cell cycle, overcoming this arrest, and then 
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entering into mitosis despite the presence of damaged DNA (Toczyski et al., 1997).   We 
used the HT-29 cell line because these cells, when treated with 25 nM CPT, fulfil the 
three features that define checkpoint adaptation (Kubara et al., 2012).  Eventually, these 
treated cells escaped the G2 phase arrest and entered into mitosis by 48 hours even 
though they have damaged DNA.  The advantage provided by the HT-29 cell line over 
the original U2OS cell model in which checkpoint adaptation was first identified in 
human cells (Syljuåsen et al., 2006) is the pronounced rounded cell morphology when 
they are in mitosis.  Furthermore, HT-29 cells are known to be arrested in mitosis 
following a treatment with antimitotic compounds rather than immediately being engaged 
in programmed cell death (Gascoigne and Taylor, 2008).  Although we did not study 
mitotic arrest in this thesis, mitotic cells (and thus checkpoint adaptation) is easier to 
detect in HT-29 cells than other cell lines such as U2OS.  Finally, the technique of 
mechanical shake-off  (Terasima and Tolmach, 1963) permits one to isolate populations 
of cells undergoing checkpoint adaptation and re-cultivate them.  These features enabled 
us to test the hypothesis that checkpoint adaptation may potentially promote genomic 
instability in cancer human cells. 
We designed our checkpoint adaptation assay by drawing from parameters that are 
relevant to the human disease of colon cancer.  For example, HT-29 cells are derived 
from human colon carcinoma tumor.  Furthermore, CPT or its derivatives, are one of the 
treatment options for patients diagnosed with colon cancer (Pizzolato and Saltz, 2003).  
We chose a concentration of CPT that was both cytotoxic for HT-29 (Larsen et al., 2001); 
 69 
 
yet within the MTD (Maximum Tolerated Dose) range of serum levels of treated patients 
(Rivory et al., 1997).   
 
 
4.2   Some HT-29 Cells That Undergo Checkpoint Adaptation Are Able To Survive 
Studies have established that most cells that undergo checkpoint adaptation 
eventually die (Syljuåsen et al., 2006; Kubara et al., 2012).  However, it has been also 
suggested that checkpoint adaptation might be a cause of genomic change in cancer cells 
(Syljuåsen et al., 2007; Bartek and Lukas, 2007).  Inherent in this suggestion was the 
possibility that some cancer cells survive checkpoint adaptation.  Therefore, we tested this 
by collecting CPT treated mitotic cells with sequential mechanical shake-off and re-
cultivating them.  We found that the majority of cells that underwent checkpoint 
adaptation had died - which was expected, as we were treating cells with a cytotoxic 
compound.  Some cells, however, underwent checkpoint adaptation and survived, and 
could be cultured for at least 12 days in our experiments.  We have used survival assay 
and clonogenic assay to determine the number of cells that survived checkpoint 
adaptation under our laboratory conditions of standard cell culture.  The survival assay 
and clonogenic assay revealed that approximately 3% and 1% of the cells that undergo 
checkpoint adaptation are able to survive CPT treatment and proliferate (CAS cells).  
Although these percentages seem small, they might be biologically significant when one 
considers the number of cells that make up a tumor.  We note, however, that we have 
collected cells after one “treatment” and detected survival cells; patients would likely 
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receive several cycles of treatment during an anti-cancer treatment regime (Pizzolato and 
Saltz, 2003).  
With the knowledge that it is possible, under experimental conditions, to collect 
and cultivate cells that survive checkpoint adaptation, it then became possible to examine 
survivors (which we call CAS cells) for genomic change.  We were motivated to examine 
this because previous results from my laboratory detected that cells undergoing 
checkpoint adaptation (i.e. mitotic) were positive for histone γ−H2AX.  We have 
examined CAS cells using different techniques to find if genomic changes had occurred. 
 
 
4.3   HT-29 CAS Cells Have Damaged DNA 
In our study, we have verified that HT-29 cells, following the treatment with CPT, 
recruited histone γ-H2AX.  Positive signals for histone γ-H2AX indicated that the cells 
have damaged DNA.  By collecting CAS cells we found that 90% of them were negative 
for histone γ-H2AX staining.  This result suggested that the CAS had likely repaired their 
genome following checkpoint adaptation.   
To determine if the CAS cells were still capable of signalling histone γ-H2AX, we 
re-treated the CAS cells with CPT. Upon retreatment, an average of 45% of the CAS cells 
was positive for histone γ-H2AX.  This result indicated some of the CAS cells lost the 
ability to display a DNA damage signal after being re-treated with CPT.  We do not know 
at which point in the DNA damage pathway the ability to signal by histone γ-H2AX was 
lost.  It might be caused by a mutation, for example in ATM or in histone γ-H2AX, or it 
 71 
 
might be due to a reduced sensitivity to CPT.  Nonetheless, one interpretation of this 
result is that the CAS population was composed of at least two cell types: those that can 
signal damaged DNA, and those that cannot when treated with a previously cytotoxic 
concentration of CPT.  This experiment provided the first evidence that some of the CAS 
cells within the population might be different from parental cells. 
Studies using histone γ-H2AX staining are widely used; however, this method is 
only able to detect a signal for damaged DNA and does not directly measure damaged 
DNA.  In my research, we examined cells for damaged DNA by directly observing DNA 
using the alkaline comet assay.  The alkaline comet assay provided an independent means 
to correlate the amount of damage with the capacity to undergo checkpoint adaptation and 
survive mitosis.  Prior to my thesis work, a demonstration of damaged DNA in CAS cells 
at the level of individual cells had not been done.  This study showed that 73% of the 
CAS cells displayed comets, whereas non-treated cells normally displayed only 9%.  We 
used the criterion that a comet must have 20% or more of the total DNA outside of the 
nucleus, as previously published (Olive et al., 1990).  The presence of comets in CAS 
cells presented supportive evidence for our observation that a large number of CAS cells 
were not recognized by anti-histone γ-H2AX antibodies when re-treated with CPT.  It 
seemed possible that a large number of CAS had damaged DNA but did not signal it.   
In previous studies in other laboratories, there are examples in which histone γ-
H2AX staining and the alkaline comet assay provide corroborative results, and there are 
examples of when they do not (as was our case with CAS cells).  Burgess et al. (2006) 
used histone γ-H2AX staining and alkaline comet assay to evaluate the response of 
 72 
 
neuroblastoma cells (SHSY-5Y cells) treated with low-dose ionizing radiation (IR). The 
results obtained from both techniques were consistent with each other. Similar results 
were found when HCT116 cells were treated with hedamycin, a DNA alkylating agent 
(Tu et al., 2005).  A positive correlation was identified between the results when using 
either the comet analysis or histone γ-H2AX fluorescence. 
 Although some laboratories found a close correlation between the result of 
immunofluorescence microscopy using histone γ-H2AX and the alkaline comet assay, it 
is not always the case.  Yu et al. (2006) used the alkaline comet assay to analyze human 
amnion cells (FL cells) treated with N-methyl-N′-nitro-N-nitrosoguanidine (MNNG). 
They found that a higher percentage of cells scored positive with the alkaline comet assay 
than they did after being stained with histone γ-H2AX antibodies and 
immunofluorescence microscopy.  Gallmeier et al. (2005) used histone γ-H2AX staining 
and alkaline comet assay on RKO colorectal cancer cells treated with norethindrone to 
test its genotoxicity.  No correlation was identified between the results when comparing 
measurements of the tail moment or histone γ-H2AX fluorescence.   
Although we favoured the notion that the histone γ-H2AX signals might be 
inactivated in some CAS cells, other explanations are possible.  The alkaline comet assay 
can detect types of damaged DNA such as abasic nucleotides, or excision sites, which 
might not provide histone γ-H2AX signals (Wood et al., 2010).  If this type of damage is 
present in some CAS cells, it might also account for the difference in the results between 
immunofluorescence microscopy using histone γ-H2AX antibodies and comet assay.  
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More detailed studies are currently being investigated in my laboratory as a result of this 
finding.   
 
 
4.4   CAS Cells and Micronuclei  
A micronucleus appears as a small membrane-bound nucleus, in addition to a 
main nucleus, which forms due to improper incorporation of acentric fragments or 
chromosomes into daughter nuclei during cell division (Fenech et al., 2011; Luzhna et al., 
2013).  Micronuclei are commonly used as evidence of chromosome and/or genome 
mutations caused by damaged DNA (Hovhannisyan et al., 2009).  We detected 
micronuclei in 2% of the CAS cells after 10-12 days of culture.  In comparison to non-
treated HT-29 cells with 1% micronuclei, these two numbers were not significantly 
different.  New data from the laboratory reveal that this number is much higher in 
samples of CAS cells taken at earlier times after checkpoint adaptation, which suggests a 
profound restructuring of the nucleus during the process of establishing a survival 
population.  Genomic change acquired in micronuclei might contribute to cancer 
development, or in this case, contribute to change in cells that are already cancerous.  
Micronuclei can also contribute to the formation of DNA breakage and chromothripsis 
(Crasta et al., 2012). 
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4.5   Chromothripsis in CAS Cells 
In this thesis, HT-29 cells were studied to investigate if there was an evidence of 
genomic change in CAS cells.  We observed pulverized, or highly broken, chromosomes 
by DAPI staining and microscopy in cells undergoing checkpoint adaptation (Figure 14C 
and Figure 16).  We have performed karyotype analysis on HT-29 cells which provided 
the opportunity to examine the outcome of the cells that survived checkpoint adaptation 
for signs of genomic change.  Results from the karyotype experiments revealed that we 
could create a mitotic event in which chromosomes shatter into tens to hundreds of pieces 
in HT-29 cells treated with CPT.  These cells might be undergoing mitotic catastrophe, 
which results from abnormal mitosis associated with the formation of micronuclei 
(Swanson et al., 1995; Ianzini and Mackey, 1997; Roninson et al., 2001).  Catastrophe 
usually occurs when chromosomes condense for mitotic cell division, in this instance 48 
hours (Stephens et al., 2011; Forment et al., 2012).  Later (in 10 to 12 days), the 
pulverized chromosomes appear to be rejoined in a mosaic patchwork of genomic 
fragments.  At a superficial level this resembles chromothripsis, although we did not test 
this directly by DNA sequencing, as had been done in the original papers describing the 
phenomenon chromothripsis (Stephens et al., 2011; Liu et al., 2011).   
Chromothripsis was also observed in the genome of a chronic lymphocytic 
leukaemia sample (CLL) (Forment et al., 2012).  Paired-end sequencing of the CLL 
sample revealed 42 chromosomal rearrangements on the long arm of chromosome 4.  
Even though the majority of rearrangements occurred in chromosome 4, other 
rearrangements were detected in chromosomes 1, 12 and 15.  Additional studies of 
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chromosome structures in other tumour samples and cell lines revealed that 
chromothripsis is present in 25% of the bone cancers (osteosarcoma and chordoma) 
(Stephens et al., 2011) and possibility in at least 2% - 3% of all human cancers, such as 
melanomas, sarcomas and gliomas, as well as colorectal, lung, oesophageal, renal, and 
thyroid cancers (Kloosterman et al., 2011; Magrangeas et al., 2011; Molenaar et al., 
2012).   
The pathways in which the cells survive checkpoint adaptation with damaged 
DNA, such as rejoining the shattered chromosome, remain unknown.  As we have 
observed, the cells were able to repair chromosomes in some manner by the time when 
we observed them at 10 to 12 days post-collection.  However, there might be a limit to 
what can be repaired because, as we have seen, approximately 99% of the cells die.  This 
suggests that the repair is not sufficient for all the cells to survive. 
 
 
4.6   Mechanisms that Regulate Chromothripsis  
The mechanisms that cause chromothripsis are not well understood.  Under 
conditions that do not include cancer treatments, one possibility is that chromothripsis is 
initiated when one or more chromosomal regions encounter a localized, ionizing radiation 
particle during mitosis, which induces breaks in one or a few chromosomes (Stephens et 
al., 2011).  Another possibility is dysfunction of telomeres, which lead to further 
chromosome breaks and rearrangements such as fusion between sister chromatids, 
aneuploidy and polyploidy.  A current hypothesis of a cause of chromothripsis is the 
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possibility that micronuclei contribute whole or partial chromosomes that shatter during 
mitosis (Crasta et al., 2012).  These pulverized chromosome segments can rearrange the 
genome if reassembled and subsequently reintegrated into the main nucleus of a daughter 
cell. 
  
 
4.7   Chromothripsis in Colon Cancer 
Chromothripsis might have a role in colon cancer.  Wigard et al. (2013) described 
a pairwise genomic analysis of matched primary and metastatic colon cancer samples 
from four patients.  They performed genome-wide mate-pair sequencing, single 
nucleotide polymorphism (SNP) array profiling, and exome sequencing to determine the 
chromosomal rearrangements that contribute to the formation of colon cancer.  Cancer 
genes, such as NOTCH2, EXO1 and MLL, are affected by breakpoints of chromothripsis 
clusters and abnormal rearrangements, as demonstrated in their studies.  They also 
confirmed mutations in 24 genes by sequencing the coding regions of a cancer exome in 
all colon tumor samples.  This study concluded that large and small chromothripsis events 
occur in every colon tumor sample, and this event is one of the contributors to 
chromosomal rearrangements.   
 Karyotype analysis of CAS cells revealed that the average number of 
chromosomes present in each cell was 35 instead of 65 (Kondoh et al., 1993; Guildbaud 
et al., 2001).  Strikingly, there was tremendous variation in this number, which suggested 
that the CAS cells in a population were not simply composed of one genomically 
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identical clone.  The variation in chromosome number in the CAS cells led us to ask if the 
chromosomes in the CAS cells maintain all the morphological characteristics of an ideal 
chromosome such as telomeres and centromeres.  Typically, telomeres are located at the 
ends of the linear chromosome, where they cap the chromosome and prevent fusions 
between the ends of different chromosomes (Bickmore, 2001).  Centromeres are located 
on sister chromatids to provide a site for microtubule attachment (Bickmore, 2001).  
Fluorescence In Situ Hybridization (FISH) analysis provided a better understanding of 
genomic rearrangements of CAS cells by confirming the presence of telomeres and 
centromeres.   
FISH analysis revealed that nearly all the chromosomes in CAS cells contained 
centromeres, as percentage that was not statistically different from the non-treated cells.  
However, we found that at least one out of four telomeres was absent in 45% of the CAS 
cells.  Moreover, 28% of the telomeres in the CAS cells were observed to be located in 
positions other than the tips of chromosomes.  The frequency of either missing or wrong 
positioning of the telomeres in the chromosomes in CAS cells suggests that genomic 
rearrangements have occurred.  Furthermore, we also found variation with these types of 
changes, suggesting that we were observing cells of more than one origin, which is 
consistent with the possibility of generating genomic variation by checkpoint adaptation.  
One limitation of this research was the inability to show exact genomic rearrangement on 
the chromosomes.  This would require other techniques such as chromosome painting 
analysis (Metzenberg, 2005) of the CAS cells or sequencing. 
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4.8   Genomic Rearrangements in CAS Cells  
 We propose three possibilities to explain the presence of genomic changes in CAS 
cells:  
1. The CAS cell originated from a cell that was already present in the HT-29 
population, it has the same genome as other cells, and it survived because it 
managed to avoid CPT treatment. 
2. The CAS cell originated from a cell that was already present in the HT-29 
population and it survived because it already had a genome that was different 
from the parental population.  
3. The CAS cell acquired a different genome by undergoing checkpoint adaptation 
and repairing its shattered genome.   
 To address these possibilities, our experiments enabled us to examine the genome 
under several different conditions and by using several different techniques.  In all cases, 
however, the technique of using mechanical shake-off helped us interpret the outcome.  
The ability of HT-29 cells to become rounded is one of the features that make them a 
valuable model to answer these types of questions.   
By collecting cells that are rounded (that were undergoing checkpoint adaptation), 
we increased the likelihood that we are studying cells that have responded to treatment by 
a genotoxic agent.  Therefore, we have reduced the possibility that we are studying cells 
that originate from prediction 1.  It remains formally more difficult to eliminate the 
possibility that we are studying a cell from prediction 2. However, the results from 
karyotyping and from FISH are more in support of prediction 3 than that of prediction 2.  
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For example, the variation in the number of chromosomes in CAS cells suggests that a 
number of different cell types are present in the CAS population.  If the CAS cells 
originated from one or two pre-existing cells, we would expect the chromosome number 
to show less variability.  Overall, these data suggest that HT-29 cells do undergo 
checkpoint adaptation when exposed to CPT, and the cells that survive checkpoint 
adaptation have a rearranged genome.  We are able to see genomic change in CAS cells at 
several levels: 
1. Karyotype analysis reveals change of chromosome numbers. 
2. Chromosome structural changes by FISH analysis 
3. The inability of some of the CAS cells to detect damaged DNA (unable 
 to signal histone γ-H2AX). 
These findings provide valuable information about the integrity of the genome of 
the CAS cells and support the hypothesis that checkpoint adaptation might cause genomic 
change in genotoxic treated human cancer cells.   
 
 
4.9    Thesis Conclusion 
The purpose of this research project was to test the hypothesis that HT-29 cells that 
survive checkpoint adaptation have changes in their genome.  To address this, I first 
established that some HT-29 cells can survive checkpoint adaptation.   
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1. Ninety percent of the HT-29 CAS cells were negative for histone γ-H2AX 
without further treatment; however, 73% of the CAS cells displayed comets, 
indicating that their genome was damaged. This phenomenon suggests that the 
genome in CAS cells might be unstable. 
 
2. CAS cells contained an average of 35 chromosomes whereas non-treated cells 
contained 65.  This provides evidence that the cells that survive checkpoint 
adaptation contain an altered genome. 
 
3. FISH analysis revealed that CAS cells appear to have changes in the 
organization of their genome as 45% of the chromosomes were missing 
telomeres and 28% of the chromosomes had telomeres in the wrong position.   
  
 
 From this research we believe CAS cells might be a source of cells that become 
resistant and cause cancer relapse following treatment.  If this is the case, an 
understanding of the mechanism of checkpoint adaptation and its outcomes might 
eventually lead to improvements in cancer treatments in the future.  For example, by 
understanding this process we can search for treatments to maintain toxicity, while 
preventing further genomic change.  One opportunity would be to explore if we can 
prevent checkpoint adaptation such as stopping mitosis with Cdk inhibitors (Bettayeb et 
al., 2008).  This would diminish the number of CAS cells.  Based on our findings, more 
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studies are being conducted in the laboratory to examine genomic change in human 
cancer cells that survive checkpoint adaptation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
 
References 
Abraham, R. 2001. Cell cycle checkpoint signaling through the ATM and ATR kinases. 
Genes and Development. 15:2177-2196. 
 
Amaral, J. D., J. M. Xavier, C. J. Steer, and C. M. Rodrigues. 2010. The role of p53 in 
apoptosis. Discovery Medicine. 9:145–152. 
 
Andreassen, P. R., O. D. Lohez, and R. L. Margolis. 2003. G2 and spindle assembly 
checkpoint adaptation, and tetraploid arrest: implications for intrinsic and 
chemically induced genomic instability. Mutation Research. 532:245-253. 
 
Bartek, J., and J. Lukas. 2007. DNA damage checkpoints: from initiation to recovery or 
adaptation. Current Opinion in Cell Biology. 19:238-245. 
 
Bartkova, J., Z. Horejsí, K. Koed, A. Krämer, F. Tort, K. Zieger, P. Guldberg, M. 
Sehested, J. M. Nesland, C. Lukas, T. Ørntoft, J. Lukas, and J. Bartek. 2005. DNA 
damage response as a candidate anti-cancer barrier in early human tumorigenesis. 
Nature. 434:864-870. 
 
Benson, A. B., D. Schrag, M. R. Somerfield, A. M. Cohen, A. T. Figueredo, P. J. Flynn, 
M. K. Krzyzanowska, J. Maroun, P. McAllister, E. V. Cutsem, M. Brouwers, M. 
Charette, and D. G. Haller. 2004. ASCO recommendations on adjuvant 
chemotherapy for stage II colon cancer. Journal of Clinical Oncology. 22:3408-
3419. 
 
Bettayeb K., N. Oumata,  A. Echalier, Y. Ferandin, J. A. Endicott, H. Galons, and L. 
Meijer. 2008. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-
dependent kinases. Oncogene. 27:5797-5807. 
 
Bickmore, W. A. 2001. Eukaryotic chromosomes. Encyclopedia of Life Sciences. 1-7. 
 
Bonner, W., C. Redon, J. Dickey, A. Nakamura, O. Sedelnikova, S. Solier, and Y. 
Pommier. 2008. GammaH2AX and cancer. Nature Reviews Cancer. 8:957-967. 
 
Bruyere, C., and L. Meijer. 2013. Targeting cyclin-dependent kinases in anti-neoplastic 
therapy. Current Opinion in Cell Biology. 25:772-779. 
 
Busino, L., M. Donzelli, M  Chiesa, D. Guardavaccaro, D. Ganoth, N. V. Dorrello, A. 
Hershko, M. Pagano, and G. F. Draetta. 2003. Degradation of Cdc25A by β-TrCP 
during S phase and in response to DNA damage. Nature. 426:87-91. 
 
 83 
 
Cahuzac, N., A. Studeny, K. Marshall, I. Versteege, K. Wetenhall, B. Pfeiffer, S. Leonce, 
 J.A. Hickman, A. Pierre, and R.M. Golsteyn. 2010. An unusual DNA binding 
 compound, S23906, induces mitotic catastrophe in cultured human cells. Cancer 
 Letters. 289:178-187. 
 
Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer 
 Statistics 2013. Toronto, ON: Canadian Cancer Society; 2013. 
 
Cassio, D. 2006. A general and reliable method for obtaining high-yield metaphasic 
preparations from adherent cell lines: rapid verification of cell chromosomal 
content. Cell Biology. 39:387-391. 
 
Castedo, M., J. L. Perfettini, T. Roumier, K. Andreau, R. Medema, and G. Kroemer. 
2004. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 
23:2825-2837. 
 
Cerveira, N., S. Bizarro, and M. Teixeira, 2012. Cancer cell cycle. Journal of the 
Portuguese Biochemical Society. 9:40-47. 
 
Champoux, J.J., 2001. DNA topoisomerases: structure, function, and mechanism. Annual 
Review of Biochemistry. 70:369-413. 
 
Clemenson, C., and M. Marsolier-Kergoat. 2009. DNA damage checkpoint inactivation: 
 adaptation and recovery. DNA Repair. 8:1101-1109. 
 
Clifford, B., M. Beljin, G. Stark, and W. Taylor. 2003. G2 arrest in response to 
 topoisomerase II inhibitors: The role of p53. Cancer Research. 63:4074-4081. 
 
Collins, A. R., V. L. Dobson, M. Dusinská, G. Kennedy, and R. Stĕtina. 1997. The comet 
 assay: what can it really tell us? Mutation Research. 375:183-193. 
 
Crasta, K., N. Ganem, R. Dagher, A. Lantermann, E. Ivanova, Y. Pan, L. Nezi, A. 
 Protopopov, D. Chowdhury, and D. Pellman. 2012. DNA breaks and chromosome 
 pulverization from errors in mitosis. Nature. 482:53-60. 
 
Fenech, M., M. Kirsch-Volders, A. Natarajan, J. Surralles, J. Crott, J. Parry, H. Norppa, 
D. Eastmond, J. Tucker, and P. Thomas. 2011. Molecular mechanisms of 
micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and 
human cells. Mutagenesis. 26:125-132. 
 
Fernandez-Capetillo, O., A. Lee, M. Nussenzweig, and A. Nussenzweig. 2004. H2AX: 
 the histone guardian of the genome. DNA Repair. 3:959-967.  
 
 84 
 
Ferry, G., A. Studeny, C. Bossard, P. M. Kubara, D. Zeyer, J. P. Renaud, P. Casara, G. de 
 Nanteuil, M. Wierzbicki, B. Pfeiffer, M. Prudhomme, S. Leonce, A. Pierré, J. A. 
 Boutin, and R. M. Golsteyn. 2011. Characterization of novel Checkpoint kinase 1 
 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase 
 inhibitors. Life Sciences. 89:259-268. 
 
Forment, J. V., A. Kaidi, and S. P. Jackson. 2012. Chromothripsis and cancer: causes and 
 consequences of chromosome shattering. Nature Reviews Cancer. 12:663- 670.  
 
Furuta, T., H. Takemura, Z. Y. Liao, G. J. Aune, C. Redon, O. A. Sedelnikova, D. R. 
 Pilch, E. P. Rogakou, A. Celeste, H. T. Chen, A. Nussenzweig, M. I. Aladjem, W. 
 M. Bonner, and Y. Pommier. 2003. Phosphorylation of histone H2AX and 
 activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA-
 double-strand breaks induced by mammalian DNA topoisomerase I cleavage 
 complexes. Journal of Biological Chemistry. 278:20303-20312. 
 
Galgoczy, D., and D. Toczyski. 2001. Checkpoint adaptation precedes spontaneous and 
damage-induced genomic instability in yeast. Molecular and Cellular Biology. 
21:1710-1718. 
 
Gallmeier, E., J. M. Winter, S. C. Cunningham, S. R. Kahn, S. E. Kern. 2005. Novel 
genotoxicity assays identify norethindrone to activate p53 and phosphorylate 
H2AX. Carcinogenesis. 26:1811-1820. 
 
Gascoigne, K. E., and S. S. Taylor. 2008. Cancer cells display profound intra- and 
interline variation following prolonged exposure to antimitotic drugs. Cancer 
Cell. 14:111-122. 
 
Giovanella, B. C., J. S. Stehlin, M. E. Wall, M. C. Wani, A. W. Nicholas, L. F. Liu, R. 
Silber, and M. Potmesil. 1989. DNA topoisomerase I-targeted chemotherapy of 
human colon cancer in xenografts. Science. 246:1046-1048. 
 
Goldwasser, F., I. Bae, M. Valenti, K. Torres, and Y. Pommier. 1995. Topoisomerase I-
related parameters and camptothecin activity in the colon carcinoma cell lines 
from the National Cancer Institute anticancer screen. Cancer Research. 55:2116-
2121. 
 
Golsteyn, R. M. 2005. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in 
apoptosis: a role beyond the cell cycle. Cancer Letters. 217:129-138. 
 
Gonzalez, L. P., F.G. Westhorpe , S.S. Taylor. 2012. The spindle assembly checkpoint. 
Current Biology. 22:966-980. 
 
 85 
 
Gottesman, M., T. Fojo, and S. Bates. 2002. Multidrug resistance in cancer: Role of ATP-
 dependent transporters. Nature Reviews Cancer. 2:48-58. 
Guilbaud, N., L. Kraus-Berthier, F. Meyer-Losic, V. Malivet, C. Chacun, M. Jan, F. 
 Tillequin, S. Michel, M. Koch, B. Pfeiffer, G. Atassi, J. Hickman, and A. Pierré. 
 2001. Marked antitumor activity of a new potent acronycine derivative in 
 orthotopic models of human solid tumors. Clinical Cancer Research. 7:2573-
 2580. 
 
Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation  
 Cell. 144:646-674. 
 
Harris, A. 1973. Location of cellular adhesions to solid substrata. Developmental Biology.  
 35:97-114. 
 
Hartwell, L. H., and T. A. Weinert. 1989. Checkpoints: controls that ensure the order of 
 cell cycle events. Science. 246:629-634. 
 
Hendzel, M. J., Y. Wei, M. A. Mancini, A. Van Hooser, T. Ranalli, B. R. Brinkley, D. P. 
 Bazett-Jones, and C. D. Allis. 1997. Mitosis-specific phosphorylation of histone 
 H3 initiates primarily within pericentromeric heterochromatin during G2 and 
 spreads in an ordered fashion coincident with mitotic chromosome condensation. 
 Chromosoma. 106:348-360. 
 
Holland, N, A. Fucic, D. F. Merlo, R. Sram, and M. Kirsch-Volders. 2011. Micronuclei 
 in neonates and children: effects of environmental, genetic, demographic and 
 disease variables. Mutagenesis. 26:51-56. 
 
Hovhannisyan, G., R. Aroutiounian, and M. Glei. 2009. Butyrate reduces the frequency of 
micronuclei in human colon carcinoma cells in vitro. Toxicology In Vitro. 
23:1028-1033. 
 
Hsiang, Y., M. Lihou, and L. Liu. 1989. Arrest of replication forks by drug-stabilized 
topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by 
camptothecin. Cancer Research. 49:5077-5082. 
 
Hübner, B., H. Strickfaden, S. Müller, M. Cremer, and T. Cremer. 2009. Chromosome 
shattering: a mitotic catastrophe due to chromosome condensation failure. 
European Biophysics Journal. 38:729-747.   
 
Ianzini, F., and M. A. Mackey. 1997. Spontaneous premature chromosome condensation 
and mitotic catastrophe following irradiation of HeLa S3 cells. International 
Journal of Radiation Biology. 72:409-21. 
 
 86 
 
Jazayeri, A., J. Falck, C. Lukas, J. Bartek, G. Smith, J. Lukas, and S. Jackson. 2006. 
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-
strand breaks. Nature Cell Biology. 8:37. 
Juan, G., F. Traganos, W. James, J. Ray, M. Roberge, D. Sauve, H. Anderson,  and Z. 
 Darzynkiewicz. 1998. Histone H3 phosphorylation and expression of cyclins A 
 and B1 measured in individual cells during their progression through G2 and 
 mitosis. Cytometry. 32:71–77. 
 
Kandoth, C., M. D. McLellan, F. Vandin, K. Ye, B. Niu, C. Lu, M. Xie, Q. Zhang, J. F. 
 McMichael, M. A. Wyczalkowski, M. D. M. Leiserson, C. A. Miller, J. S. Welch, 
 M. J. Walter, M. C. Wendl, T. J. Ley, R. K. Wilson, B. J. Raphael and L. Ding. 
 2013. Mutational landscape and significance across 12 major cancer types. 
 Nature. 502:333-339. 
 
Kastan, M., and J. Bartek. 2004. Cell-cycle checkpoints and cancer. Nature. 432:316-323. 
 
Kawai, K., C. Viars, K. Arden, D. Tarin, V. Urquidi, and S. Goodison. 2002. 
Comprehensive karyotyping of the HT-29 colon adenocarcinoma cell line. Genes, 
Chromosomes & Cancer. 34:1-8. 
 
Kerbel, R. 1997. A cancer therapy resistant to resistance. Nature. 390:335-336. 
 
Kerr, J., A. Wyllie, and A. Currie. 1972. Apoptosis: A basic biological phenomenon with 
wide-ranging implications in tissue kinetics. British Journal of Cancer. 26:239-
257. 
 
Kloosterman, W. P., M. Hoogstraat, O. Paling, M. Tavakoli-Yaraki, I. Renkens, J. S. 
Vermaat, M. J. van Roosmalen, S. van Lieshout, I. J. Nijman, W. Roessingh, R. 
van 't Slot, J. van de Belt, V. Guryev, M. Koudijs, E. Voest, and E. Cuppen. 2011. 
Chromothripsis is a common mechanism driving genomic rearrangements in 
primary and metastatic colorectal cancer. Genome Biology. 12:R103. 
 
Kondoh, N., C. Schweinfest, T. Papas. 1993. Chromosomal alterations in permanently 
differentiated ht29 colon-carcinoma cells induced with sodium-butyrate. 
International Journal of Oncology. 3:177-83. 
 
Korbel, J. O., and P. J. Campbell. 2013. Criteria for inference of chromothripsis in cancer 
genomes. Cell. 152:1226-1236. 
 
Kubara, P., S. Kerneis-Golsteyn, A. Studeny, B. Lanser, L. Meijer, and R.M. Golsteyn. 
2012. Human cells enter mitosis with damaged DNA after treatment with 
pharmacological concentrations of genotoxic agents. Biochemical Journal. 
446:373-381. 
 
 87 
 
Lancaster, O. M., M. L. Berre, A. Dimitracopoulos, D. Bonazzi, E. Zlotek-Zlotkiewicz, 
R. Picone, T. Duke, M. Pielsend, and B. Baum. 2013. Mitotic rounding alters cell 
geometry to ensure efficient bipolar spindle formation. Developmental Cell. 25: 
270-283. 
 
Larsen, A. K., C. Gilbert, G. Chyzak, S. Y. Plisov, I. Naguibneva, O. Lavergne, L. 
Lesueur-Ginot, and D. C. Bigg. 2001. Unusual potency of BN 80915, a novel 
fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. 
Cancer Research. 61:2961-2967. 
 
Leibovitz, A., and K. C. Mazur. 1977. A generation-time technique. TCA manual / Tissue 
Culture Association. 3:655-657. 
 
Léonce, S., L. Kraus-Berthier, R. M. Golsteyn, M. H. David-Cordonnier, C. Tardy, A. 
Lansiaux, V. Poindessous, A. K. Larsen, and A. Pierré. 2006. Generation of 
replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-
1. Cancer Research. 66:7203-7210. 
 
Li, Q.Y., Y.G. Zu, R. Z. Shi, and L.P. Yao. 2006. Review Camptothecin: current 
perspectives. Current Medical Chemistry. 13:1-19. 
 
Liu, P., A. Erez, S. C. Nagamani, S. U. Dhar, K. E. Kołodziejska, A. V. Dharmadhikari, 
M. L. Cooper, J. Wiszniewska, F. Zhang, M. A. Withers, C. A. Bacino, L. D. 
Campos-Acevedo, M. R. Delgado, D. Freedenberg, A. Garnica, T. A. Grebe, D. 
Hernández-Almaguer, L. Immken, S. R. Lalani, S. D. McLean, H. Northrup, F. 
Scaglia, L. Strathearn, P. Trapane, S. H. Kang, A. Patel, S. W. Cheung, P. J. 
Hastings, P. Stankiewicz, J. R. Lupski, and W. Bi. 2011. Chromosome 
catastrophes involve replication mechanisms generating complex genomic 
rearrangements. Cell. 146:889-903.  
 
Liu, Q., S. Guntuku, X. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-
Rivera, F. DeMayo, A. Bradley, L. Donehower, and S. Elledge. 2000. Chk1 is an 
essential kinase that is regulated by ATR and required for the G2/M DNA damage 
checkpoint. Genes and Development. 14:1448-1459. 
 
Lundgren, K., N. Walworth, R. Booher, M. Dembski, M. Kirschner, and D. Beach. 1991. 
Mik1 and Wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. 
Cell. 22:1111-1122. 
 
Luzhna, L., P. Kathiria, and O. Kovalchuk. 2013. Micronuclei in genotoxicity 
assessment: from genetics to epigenetics and beyond. Frontiers in Genetics. 
4:131, 1-17. 
 
 88 
 
Magrangeas, F., H. Avet-Loiseau, N. C. Munshi, and S. Minvielle. 2011. Chromothripsis 
identifies a rare and aggressive entity among newly diagnosed multiple myeloma 
patients. Blood. 118:675-678.  
Maher, C. A., and R. K. Wilson. 2012. Chromothripsis and human disease: piecing 
 together the shattering process. Cell. 148:29–32. 
 
Mailand, N., J. Falck, C. Lukas, R. G. Syljuasen, M. Welcker, J. Bartek, and J. Lukas. 
2000.  Rapid destruction of human Cdc25A in response to DNA damage. Science 
288:1425-1429. 
 
McLachlan-Burgess, A., S. McCarthy, C. Griffin, J. Richer, R. G. Cutler, and S. Pandey. 
2006. Differential response induced by exposure to low-dose ionizing radiation in 
SHSY-5Y and normal human fibroblast cells. Applied Biochemistry and 
Biotechnology. 135:159-178. 
 
McManus, K. J., and M. J. Hendzel. 2005. ATM-dependent DNA damage-independent 
mitotic phosphorylation of H2AX in normally growing mammalian cells. 
Molecular Biology of the Cell. 16:5013-5025. 
 
Medema R.H., L. Macůrek. 2011. Checkpoint control and cancer. Oncogene. 31:2601-
2603. 
 
Meijer, L., D. Arion, R. Golsteyn, J. Pines, L. Brizuela, T. Hunt, and D. Beach.1989. 
Cyclin is a subunit of the sea urchin M-phase specific histone Hl kinase. EMBO 
Journal. 8:2275-2282. 
 
Melo, J., and D. Toczyski. 2002. A unified view of the DNA-damage checkpoint. Current 
Opinion in Cell Biology. 14:237-245. 
 
Metzenberg, S. 2005. Chromosome painting, a powerful tool for chromosomal analysis. 
California State University Lecture Series. www.escience.ws/b572/L23/L23.htm. 
 
Molenaar, J. J., J. Koster, D. A. Zwijnenburg, P. van Sluis, L. J. Valentijn, I. van der 
Ploeg, M. Hamdi, J. van Nes, B. A. Westerman, J. van Arkel, M. E. Ebus, F. 
Haneveld, A. Lakeman, L. Schild, P. Molenaar, P. Stroeken, M. M. van Noesel, I. 
Øra, E. E. Santo, H. N. Caron, E. M. Westerhout and R. Versteeg. 2012. 
Sequencing of neuroblastoma identifies chromothripsis and defects in 
neuritogenesis genes. Nature. 483:589–593. 
 
Morgan, M. A., L. A. Parsels, J. D. Parsels, T. S. Lawrence, and J. Maybaum. 2006. The 
relationship of premature mitosis to cytotoxicity in response to checkpoint 
abrogation and antimetabolite treatment. Cell Cycle. 5:1983-1988. 
 
 89 
 
Mustafa, O. H., A. R. Hamzeh, L. Ghabreau, N. Akil, A. Almoustafa, and A. Alachkar. 
2013. Allele frequencies of the epidermal growth factor receptors polymorphism 
R521K in colorectal cancer patients and healthy subjects indicate a risk-reducing 
effect of K521 in Syrian population. North American Journal of Medical Sciences. 
5:202–206. 
 
Nakada, S., Y. Katsuki, I. Imoto, T. Yokoyama, M. Nagasawa, J. Inazawa, and S. 
Mizutani. 2006. Early G2/M checkpoint failure as a molecular mechanism 
underlying etoposide-induced chromosomal aberrations. Journal of Clinical 
Investigation. 116:80-89. 
 
Nigg, E.A. 1995. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell 
cycle. Bioessays. 17:471-480. 
 
Niida H., and M. Nakanishi. 2006. DNA damage checkpoints in mammals. Mutagenesis. 
21:3-9. 
 
Nitiss, J. 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews 
Cancer. 9:338-350. 
 
Norbury, C., and P. Nurse. 1992. Animal cell cycles and their control. Annual Review of 
Biochemistry. 61:441-470. 
 
Olive, P. L., J. P. Banáth, and R. E. Durand. 1990. Detection of etoposide resistance by 
measuring DNA damage in individual Chinese hamster cells. Journal of the 
National Cancer Institute. 82:779-83. 
 
On, K. F., Y. Chen, H. T. Ma, J. P. Chow, and R.Y. Poon. 2011. Determinants of mitotic 
catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01. 
Molecular Cancer Therapeutics. 10:784-794. 
 
Palou, G., R. Palou, A. Guerra-Moreno, A. Duch, A. Travesa, and D. G. Quintana. 2010. 
Cyclin regulation by the S phase checkpoint. Journal of Biological Chemistry. 
285:26431–26440.   
 
Pizzolato, J., and L. Saltz. 2003. The camptothecins. Lancet. 361:2235-2242. 
 
PNA Bio Inc. 2012. PNA FISH (Fluorescence In Situ Hybridization). 
www.pnabio.com/pdf/ FISH_protocol_PNABio.pdf. 
 
Pommier, Y. 2006. Topoisomerase I inhibitors: camptothecins and beyond. Nature 
Reviews Cancer. 6:789-802. 
 
 90 
 
Rex, D. K., C. J. Kahi, B. Levin, R. A. Smith, J. H. Bond, D. Brooks, R. W. Burt, T. 
Byers, R. H. Fletcher, N. Hyman, D. Johnson, L. Kirk, D. A. Lieberman, T. R. 
Levin, M. J. O'Brien, C. Simmang, A. G. Thorson, and S. J. Winawer. 2006. 
Guidelines for colonoscopy surveillance after cancer resection: a consensus 
update by the American cancer society and US multi-society task force on 
colorectal cancer. CA: A Cancer Journal for Clinicians. 56:160–167. 
 
Rezacova, M., G. Rudolfova, A. Tichy, A. Bacikova, D. Mutna, R. Havelek, J. Vavrova, 
K. Odrazka, E. Lukasova, and S. Kozubek. 2011. Accumulation of DNA damage 
and cell death after fractionated irradiation. Radiation Research. 175:708-718. 
 
Rieder, C., and A. Khodjakov. 2003. Mitosis through the microscope: advances in seeing 
inside live dividing cells. Science. 300:91-96. 
 
Rivory, L. P., M. C. Haaz, P. Canal, F. Lokiec, J. P. Armand, and J. Robert. 1997. 
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major 
plasma metabolites in patients enrolled in phase I/II trials. Clinical Cancer 
Research. 3:1261-1266. 
 
Roca, J. 1995. The mechanisms of DNA topoisomerases. Trends in Biochemical Sciences. 
20:156-160. 
 
Rogakou, E., D. Pilch, A. Orr, V. Ivanova, and W. Bonner. 1998. DNA double-stranded 
breaks induce histone H2AX phosphorylation on serine 139. Journal of Biological 
Chemistry. 273:5858-5868. 
 
Roninson, I. B., E. V. Broude, and B. D. Chang. 2001. If not apoptosis, then what? 
Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug 
Resistance Updates. 4:303-313. 
 
Rudner, A., and A. Murray. 1996. The spindle assembly checkpoint. Current Opinion in 
Cell Biology. 8:773-780. 
 
Sancar, A., L. A. Lindsey-Boltz, K. Unsal-Kaçmaz, and S. Linn. 2004. Molecular 
 mechanisms of mammalian DNA repair and the DNA damage checkpoints.  
 Annual Review of Biochemistry. 73:39-85. 
 
Sandell, L., and V. Zakian. 1993. Loss of a yeast telomere: Arrest, recovery, and 
chromosome loss. Cell. 75:729-739. 
 
Schrag, D., L. D. Cramer, P. B. Bach, and C. B. Begg. 2001. Age and adjuvant 
chemotherapy use after surgery for stage III colon cancer. Journal of the National 
Cancer Institute. 93: 850-857. 
 
 91 
 
Siegel, R., E. Ward, O. Brawley, and A. Jemal. 2011. Cancer statistics, 2011: the impact 
of eliminating socioeconomic and racial disparities on premature cancer deaths. 
CA: A Cancer Journal for Clinicians. 61:212-236. 
 
Smith, J., L. Tho, N. Xu, and D. Gillespie. 2010. The ATM-Chk2 and ATR-Chk1 
pathways in DNA damage signaling and cancer. Advances in Cancer Research. 
108:73-112. 
 
Smith, P. J., T. A. Makinson, and J. V. Watson. 1989. Enhanced sensitivity to 
camptothecin in ataxia-telangiectasia cells and its relationship with the expression 
of DNA topoisomerase I. International Journal of Radiation Biology. 55:217-231. 
 
Sorensen, C., R. G. Sylijuasen, J. Falck, T. Schroeder, L. Rönnstrand, K. K. Khanna, B. 
B. Zhou, J. Bartek, and J. Lukas. 2003. Chk1 regulates the S phase checkpoint by 
coupling the physiological turnover and ionizing radiation-induced accelerated 
proteolysis of Cdc25A. Cancer Cell. 3:247-258. 
 
Stein, A., D. Atanackovic, and C. Bokemeyer. 2011. Current standards and new trends in 
the primary treatment of colorectal cancer. European Journal of Cancer. 47:312–
314. 
 
Stephens, P. J., C. D. Greenman, B. Fu, F. Yang, G. R. Bignell, L. J. Mudie, E. D. 
Pleasance, K. W. Lau, D. Beare, L. A. Stebbings, S. McLaren, M. L. Lin, D. J. 
McBride, I. Varela, S. Nik-Zainal, C. Leroy, M. Jia, A. Menzies, A. P. Butler, J. 
W. Teague, M. A. Quail, J. Burton, H. Swerdlow, N. P. Carter, L. A. Morsberger, 
C. Iacobuzio-Donahue, G. A. Follows, A. R. Green, A. M. Flanagan, M. R. 
Stratton, P. A. Futreal, and P. J. Campbell. 2011. Massive genomic rearrangement 
acquired in a single catastrophic event during cancer development. Cell. 144:27-
40. 
 
Strausfeld, U., J. C. Labbé, D. Fesquet, J. C. Cavadore, A. Picard, K. Sadhu, P. Russell, 
and M. Dorée. 1991. Dephosphorylation and activation of a p34cdc2/cyclin B 
complex in vitro by human CDC25 protein. Nature. 351:242-245. 
 
Swanson, P. E., S. B. Carroll, X. F. Zhang, and M. A. Mackey. 1995. Spontaneous 
premature chromosome condensation, micronucleus formation, and non-apoptotic 
cell death in heated HeLa S3 cells. Ultrastructural observations. American Journal 
of Pathology. 146:963-971. 
 
Syljuåsen, R. G. 2007. Checkpoint adaptation in human cells. Oncogene. 26:5833–5839. 
 
Syljuåsen, R., S. Jensen, J. Bartek, and J. Lukas. 2006. Adaptation to the ionizing 
radiation-induced G(2) checkpoint occurs in human cells and depends on 
 92 
 
checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Research. 66:10253-
10257. 
 
Terasima, T., and L. Tolmach. 1963. Growth and nucleic acid synthesis in synchronously 
dividing populations of HeLa cells. Experimental Cell Research. 30:344-362. 
The Cancer Genome Atlas Research Network, J. N. Weinstein, E. A. Collisson, G. B. 
 Mills, K. R. M. Shaw, B. A. Ozenberger, K. Ellrott, I. Shmulevich, C. Sander, and 
 J. M. Stuart. 2013. The cancer genome atlas pan-cancer analysis project. Nature 
 Genetics.  45:1113–1120. 
 
Toczyski, D., D. Galgoczy, and L. Hartwell. 1997. CDC5 and CKII control adaptation to 
the yeast DNA damage checkpoint. Cell. 90:1097-1106. 
 
Tu, L. C., S. Matsui, and T. A. Beerman. 2005. Hedamycin, a DNA alkylator, induces 
 γH2AX and chromosome aberrations: Involvement of phosphatidylinositol 3-
 kinase–related kinases and DNA replication fork movement. Molecular Cancer 
 Therapeutics. 4:1175-1185. 
 
Vakifahmetoglu, H., M. Olsson, and B. Zhivotovsky. 2008. Death through a tragedy: 
mitotic catastrophe. Cell Death and Differentiation. 15:1153-1162. 
 
Vermeulen, K., D. R. Van Bockstaele, and Z. N. Berneman. 2003. The cell cycle: a 
review of regulation, deregulation and therapeutic targets in cancer. Cell 
Proliferation. 36:131-149.  
 
Wall, M.E., M.C. Wani, C.E. Cook, K.H. Palmer, A.T. McPhail, and G.A. Sim. 1966. 
Plant antitumor agents. I. The isolation and structure of camptothecin, a novel 
alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. Journal of 
the American Chemical Society. 88:3888-3890. 
 
Wang, X., Y. Zhu, K. Lui, Q. Cai, P. Lu, and R. Poon. 2008. Aberrant polo-like kinase 1-
Cdc25A pathway in metastatic hepatocellular carcinoma. Clinical Cancer 
Research. 14:6813-6820. 
 
Ware, J. H., Z. Zhou, J. Guan, A. R. Kennedy, and L. Kopelovich. 2007. Establishment of 
human cancer cell clones with different characteristics: a model for screening 
chemopreventive agents. Anticancer Research. 27:1-16. 
 
Watanabe, T., T. Wu, P. J. Catalano, T. Ueki, R. Satriano, D. G. Haller, A. B. Benson, 
and S. R. Hamilton. 2001. The New England Journal of Medicine. 344:1196-1206. 
 
Weinert, Ted. 1998. DNA damage checkpoints update: getting molecular. Current 
Opinion in Genetics and Development. 8:185-193. 
 
 93 
 
Wood, D. K., D. M. Weingeistb, S. N. Bhatia, and B. P. Engelwardb. 2010. Single cell 
trapping and DNA damage analysis using microwell arrays. Proceedings of the 
National Academy of Sciences. 107:10008-10013. 
 
Yoo, H., A. Kumagai, A. Shevchenko, A. Shevchenko, and W. Dunphy. 2004. Adaptation 
of a DNA replication checkpoint response depends upon inactivation of Claspin 
by the Polo-like kinase. Cell. 117:575-588. 
 
Yu, Y., W. Zhu, H. Diao, C. Zhou, F. F. Chen, and J. Yanga. 2006. A comparative study 
of using comet assay and γH2AX foci formation in the detection of N-methyl-N′-
nitro-N-nitrosoguanidine-induced DNA damage. Toxicology in Vitro. 20:959–965. 
 
Zhao, H., and H. Piwnica-Worms. 2001. ATR-mediated checkpoint pathways regulate 
phosphorylation and activation of human Chk1. Molecular and Cellular Biology. 
21:4129-4139. 
 
Zhou, B., and S. Elledge. 2000. The DNA damage response: putting checkpoints in 
perspective. Nature. 408:433-439. 
 
